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Since their introduction in the late 20th century, therapeutic proteins have become an 
irreplaceable class of pharmaceuticals and are today used to treat a wide variety of 
diseases ranging from arthritis, diabetes, and various cancers to more recently, for 
example, asthma and migraine. In ophthalmology, the treatment of certain 
neurodegenerative diseases of the retina, such as age-related macular degeneration and 
diabetic retinopathy, has been revolutionized by therapeutic proteins that combat the 
pathological growth of abnormal blood vessels in the retina. As retinal diseases are 
some of the leading causes of vision loss and blindness globally, and expected to grow 
in prevalence with aging populations, the importance and need for such 
ophthalmologic therapeutic proteins is expected to increase. 
During the early development of therapeutic protein candidates, the production 
of functional protein in adequate amounts can often be a significant roadblock. In this 
thesis, the expression of soluble recombinant human ciliary neurotrophic factor 
(rhCNTF) – a neuroprotective protein with therapeutic potential against retinal 
neurodegeneration – in Escherichia coli was enhanced. Codon optimization of the 
hCNTF gene was combined with screening of different culture media, culture 
conditions, and fusion partners to pinpoint ideal expression conditions for rhCNTF. 
Following expression in the determined optimal conditions, the protein was purified 
with immobilized metal-ion affinity chromatography and gel filtration, and the in vitro 
activity of purified rhCNTF was demonstrated in a binding assay with its cognate 
receptor, CNTFRα. Overall, an 8–9 fold increase in soluble rhCNTF fraction and a 
10–20 fold increase in yield was achieved, whereas earlier efforts to produce CNTF 
have commonly required purification from insoluble inclusion bodies and/or yielded 
low protein amounts. Furthermore, such a combinatorial approach is successful as a 
screening strategy for soluble expression and could be applied to other proteins of 
pharmaceutical interest. 
When taken out of their natural biological milieus, most proteins are only 
marginally stable and susceptible to environmental perturbations. As such, the 
formulation of a therapeutic protein aims to protect the protein and retain its stability 
and biological activity, and ultimately to guarantee the therapeutic efficacy and safety 
throughout the lifetime of the pharmaceutical. Here, further characterization, 
formulation, and stability studies were carried out with purified rhCNTF. The proper 
folding of purified rhCNTF was observed with circular dichroism spectroscopy and 
the biological activity of the protein was verified in a cell proliferation study with a 
CNTFα expressing cell-line. After screening, two buffers were chosen as storage 
buffers for rhCNTF. Whereas minute changes in rhCNTF’s oligomeric status were 
observed in only of these buffers, no changes in rhCNTF’s thermal stability were 
observed in either buffer during the study period. As such, these results provide a basis 
for further formulation development for rhCNTF. 
Although intravitreally injected therapeutic proteins have become the 
cornerstone in the management of retinal neovascularization, how and to what extent 
these and other proteins penetrate into the retina remains poorly understood. Here, 
permeation into the neural retina was observed with fluorescently labeled rhCNTF in 
ex vivo retinal explant models. Our results indicate that permeation to the CNTF-




neuroprotective actions. Moreover, our results provide further impetus to utilize ex 
vivo methods to systematically elucidate the retinal permeation and ocular 
pharmacokinetics of therapeutic proteins by and large. 
Therapeutic proteins have not only held the helm of best-selling pharmaceuticals 
for some time now, but currently also represent more than 40% of new 
pharmaceuticals in the development pipeline. Regardless, protein drug development 
has been plagued with ever increasing development costs yet with fewer new drugs 
entering the market, and there is an urgent call to disrupt this unsustainable cycle. 
While reasons for failure are diverse, for therapeutic proteins the most reported are 
poor therapeutic efficacy and immune responses, issues which are often encountered 
relatively late during the drug development workflow. Therefore, it would be of 
utmost utility to develop methods for detecting such susceptibility before significant 
effort and funds are spent in the development of less than ideal candidates. In this 
thesis, by integrating cell-free protein synthesis in small volumes together with split-
intein mediated capture and light-triggered release, a streamlined platform for rapid 
protein production and screening was developed. Our results provide a proof-of-
principle, with successful capture and release of protein of interest, as well as protein 
bioconjugation achieved using hCNTF as a model protein. The developed platform 
can be used for the rapid screening of therapeutic protein candidate producibility, and 
acts as a first module to be coupled to in-line assays for monitoring e.g. the candidate’s 
immunogenic potential, enabling such issues to be addressed/resolved already during 
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The development of new drugs is an enormous undertaking with scarce initial 
guarantees of success. It has been estimated that it can, on average, take over 12 years 
to get a new drug on the market and that up to 2.6 billion USD in costs can mount 
during this development and in post-approval follow-up. Regardless of the invested 
time and resources, most drug candidates fail before and during clinical trials due to a 
variety of reasons, and only a very small fraction of initial candidates are eventually 
launched and reach the clinic (Paul et al., 2010; DiMasi et al., 2016). Once in the 
clinic, it is often the profits from only the best-selling – so-called blockbuster 
pharmaceuticals – that eventually cover the development costs, both their own and 
those of all their failed, discontinued, and shelved ‘peers’. It is a commonly held view 
that the current situation is in no way sustainable, and that a true paradigm shift is 
needed if new drugs are to enter the market at the current pace in the future (Scannell 
et al., 2012). 
Using proteins as pharmaceuticals to treat diseases is tempting, as they are 
involved in a myriad of biological processes, so much so that they are often referred 
to as the ‘workhorses’ of the body. Due to their biological functions, roles and mode(s) 
of action, proteins are often considerably specific in their actions and thus elicit 
relatively few adverse effects via off-target actions and given their ‘self’ origin. 
Moreover, their innovative and novel therapeutic applications can open possibilities 
to treating diseases that have been historically undruggable – hard or even impossible 
to treat – with traditional small-molecule drugs. This once distant idea of using 
proteins as therapeutics has been a tangible reality for decades now, and protein 
therapeutics have since become an important and continuously expanding class of 
pharmaceuticals, finding frequent use and an integral role in the treatment of many 
different diseases such as cancer, diabetes, and hemophilia (Leader et al., 2008). 
The mere size of therapeutic proteins alone makes them very dissimilar from 
small-molecule drugs (Wan, 2016). Small-molecule drugs are generally no larger than 
1,000 Da in mass and are chemically comparatively simple. Therapeutic proteins, on 
the other hand, are macromolecules composed of amino acids as their constituent 
monomers, and range in mass from a few thousand Da to more than 150,000 Da; a 
therapeutic protein can have between a few dozen and a few hundred amino acid 
residues and may also include diverse post-translational modification. Furthermore, 
while small-molecule drugs can rather straightforwardly be described as, for example, 
anionic or cationic and lipophilic or hydrophilic, proteins are much more complex and 
hence challenging to characterize.  The 20 different amino acids found in natural 
proteins’ structures have distinctive and diverse characteristics, therefore different 
regions in a single protein molecule can differ significantly in aromaticity, polarity, 
charge and hydro/lipophilicity. Indeed, with increasing size comes increasing 
complexity. 
Therapeutic proteins, due to their biological nature, behave differently in the 
body compared to small-molecule drugs (Shi, 2014). Pharmacologically – how the 
drug affects the body – small molecules often act as effector molecules that alter a 
macromolecule’s function by binding to it, whereas therapeutic proteins themselves 
are often the affectors. Likewise, as the pharmacokinetics – how the body handles and 




tangible manifestation of all these differences is in dosing; administering therapeutic 
proteins in conventional dosage forms, such as capsules or tablets, is not feasible and 
practically all protein drugs are currently administered parenterally, most often as 
injections and/or infusions. 
Regardless of notable advantages over small molecule drugs, proteins are 
pharmaceutically far from ideal and there are notable obstacles and limitations to their 
utilization (Morrow & Felcone 2004; Vugmeyster et al., 2012; Lagassé et al., 2017).  
As complex molecules proteins are intrinsically unstable, especially when taken out 
of their native biological contexts. Proteins remain stable and functional in only a 
narrow window of conditions; changes in the surrounding environment such as pH, 
ionic strength and temperature, can lead to degradation and/or denaturation, and 
subsequent loss of a protein’s function. Whereas small-molecule drugs can be 
synthesized in well-defined and controlled processes, this is less feasible for most full-
size proteins. Hence, they are produced by exploiting the protein synthesis 
‘machinery’ of living organisms, i.e., an expression host. This precondition alone 
gives rise to significantly different requirements, for example, in their analysis, 
characterization, formulation, and manufacture in general. While expressed proteins 
might remain relatively stable when still inside the expression host, the situation often 
changes dramatically when the protein is extracted from the biological context of the 
cells and becomes exposed to widely varying conditions and environments during 
downstream processing. Since the manufacturing workflow can involve countless 
process steps, each with the potential of adversely affecting the protein, therapeutic 
protein production is far from trivial, but instead highly complex with oftentimes 
merely procuring enough pure and biologically active protein being the biggest 
obstacle, especially during early phases of development. Pinpointing optimal 
expression conditions for even a single protein can be tedious and time-consuming. 
Instead, using rapid screening methods to assess the overall producibility of active 
protein could be utilized to increase throughput and to improve the chances for 
success. 
Ophthalmology is one such field that would benefit from improved screening 
methods for new therapeutic proteins candidates. Many degenerative diseases of the 
posterior eye segment, and more specifically the retina (the light-sensing neural tissues 
at the back of the eye), lead to partial or even full vision loss over time, taking a huge 
toll on the patients’ quality of life (Awwad et al., 2017). Furthermore, these diseases 
also exert considerable pressure on the healthcare system, especially since many of 
them are age-related and predicted to increase significantly in prevalence with the 
ageing population. Currently, the majority of both development- and clinical-stage 
treatments for these diseases are therapeutic proteins. 
Treating diseases that affect the retina is challenging (del Amo et al., 2017). Due 
to the physiology of the eye, this site is essentially isolated from the rest of the body 
and thus very difficult to reach with conventional means such as after intravenous or 
per oral administration. Owing to their characteristics such as large size and 
hydrophilicity, therapeutic proteins cannot permeate through tissues of the anterior 
eye segment – the outer, visible part of the eye – and cannot be administered topically 
(i.e., as eye drops or gels). For similar reasons, therapeutic proteins administered via 
the bloodstream cannot enter the retina. Hence, to achieve therapeutically efficient 




to the posterior part of the eye as direct intravitreal (IVT) injections every 1 to 3 
months. Considerable effort has been undertaken to make these drugs more amenable 
for administration via other routes and – even if direct injections are still unavoidable 
in the future – to make it possible to administer them less frequently. Nonetheless, the 
retinal penetration and permeation of these molecules is poorly quantitated and 
understood even with IVT-injected therapeutic proteins currently in routine clinical 
use. 
This thesis focuses on therapeutic proteins, their development, and in particular 
their use in treating diseases of the posterior eye segment. Emphasis is placed on 
experimental work carried out to optimize the production of ciliary neurotrophic factor 
(CNTF) – a protein with potential utility in treating neurodegenerative diseases – while 
also addressing its characterization and the ex vivo retinal pharmacokinetics of the 
produced CNTF. Experimental results presented herein contribute to the knowledge 
on CNTF by 1) providing a framework for enhanced production of soluble CNTF, 2) 
demonstrating the applicability of using ex vivo methods to study retinal penetration 
of proteins and 3) presenting a novel platform for the rapid screening of 




2 Review of the literature 
2.1 The before, now, and then of therapeutic proteins 
2.1.1 Dawn of the first therapeutic protein 
The concept of using proteins to manage and treat diseases is not new as proteins have 
been applied as therapeutic agents for almost a century. Insulin was first discovered 
and isolated in 1921-1922 and its utilization in the treatment of diabetes mellitus was 
quickly established (Rosenfeld, 2002; Leader et al., 2008). At first, insulin purified 
from crude bovine and porcine pancreas extracts was used, however the supply of 
animal pancreata, variations in potency, and immunological reactions in some patients 
were among the plentiful hurdles to overcome (Leader et al., 2008; Quainzon & 
Cheikh, 2012). Although gradual improvements in insulin purity and prolongation of 
the action were steadfastly achieved, insulin sourced from animals remained the only 
way to treat diabetes for decades (Rosenfeld, 2002; Leader et al., 2008). 
The pioneering work of Watson, Crick and Franklin lead to the discovery of 
DNA in 1953 (Watson & Crick, 1953). Work on DNA remained vigorous during the 
following decades, and subsequent advances in molecular biology and molecular 
cloning lead to development of recombinant DNA technology, which in 1978 was 
successfully utilized in the expression of human insulin in Escherichia coli bacterial 
cells (Goeddel et al., 1979; Johnson, 1983). This work culminated in 1982 when 
Humulin®, the first protein obtained via recombinant DNA technology and produced 
in E. coli, received marketing approval (Johnson, 1983; Carter, 2011). 
2.1.2 Maturation and sophistication 
In wake of Humulin’s success, other proteins followed suit and in 1986 the first 
therapeutic monoclonal antibody (mAb), Orthoklone OKT3® (muromonab-CD3), 
was approved for counteracting kidney transplant rejection (Ecker et al., 2015), 
followed by with Roferon A® (Interferon α) for the treatment of, i.a., hairy cell 
leukemia (Gutterman, 1994). Notable following breakthroughs include the step-wise 
humanization of mAbs: the first chimeric antibody fragment ReoPro® (abciximab), 
was approved in 1994 while the year 1997 saw the approval of rituximab (Rituxan®), 
the first chimeric full-size mAb (Brekke & Sandlie, 2003) – and also the first mAb 
implemented in oncology (Pierpont et al., 2018) – as well as the first humanized mAb 
Zenapax® (daclizumab) (Almagro & Fransson, 2008). Ultimately, the first fully 
human mAb Humira® (adalimumab), and the first to be derived via phage display 
technology, was authorized in 2002 (Osbourn et al., 2005). Other technological 
milestones include the launch of the first Fc-fusion protein therapeutic Enbrel® 
(etanercept) in 1998 (Watier & Reichert, 2017), the 2006 approval of Atryn® 
(antithrombin alfa) as the first approved biological1 obtained from a transgenic animal 
(Carroll, 2006), the 2012 the approval of the first plant-based biopharmaceutical, 
 
1 The terms with products of pharmaceutical biotechnology are often used interchangeably and their 
meanings can differ between fields of science, inside the industry and between regulatory bodies. While 
the terms ‘biological’, ‘biological medicine’ and ‘biological product’ are used to refer to, e.g., 
therapeutic proteins, vaccines, nucleic acid drugs, gene therapy, and cell therapy, ‘biological’ will 




Elelyso® (taliglucerase alfa), (Fox, 2012) and of Poteligeo® (mogamulizumab), the 
first glyco-engineered mAb (Beck & Reichert, 2012), and ultimately the emergence 
of cell-free protein synthesis (CFPS) for the production of protein therapeutics 
(Casteleijn et al., 2013),  
2.1.3 Indications and classification of therapeutic proteins 
Biologicals are used for varying indications (Walsh, 2014). Whereas hematology and 
oncology are the biggest therapeutic areas for biologicals, they have been clinically 
applied i.a. in dermatology, endocrinology, immunology and rheumatology (Lagassé 
et al., 2017). Although the majority of both existing and emerging biologicals still fall 
within these ‘traditional’ therapeutic areas (Walsh, 2014), the use of biologicals has in 
recent years also branched into treatment of asthma (Markham, 2018), chronic pain 
(Patel et al., 2018), hypercholesterolemia (Chaudhary et al., 2017), infectious diseases 
(Sparrow et al., 2017), multiple sclerosis (Heliopoulos & Patousi, 2018), and even 
migraine prevention (Tepper, 2018). The use of proteins, however, is not solely limited 
to therapy as they are also utilized in diagnostics and as vaccines (Leader, 2008; 
Walsh, 2014). 
Regardless of various applications, therapeutic proteins can be categorized in 
several ways, e.g., based on their molecular types and on molecular mechanisms of 
their activities (Carter, 2011; Dimitrov, 2012; Usmani et al., 2017). A now commonly 
accepted classification system organizes protein therapeutics based on their function 
and therapeutic applications (Leader et al., 2008; Fig. 1). Accordingly, protein 
therapeutics are organized depending on their pharmacological activities into groups 
where proteins: I) have enzymatic or regulatory activity, II) have special targeting 
activity, III) are used as vaccines, and IV) are used in diagnostics. Groups I & II can 
be further subdivided based on more specific physiological/therapeutic roles of the 
proteins as they: Ia) replace a deficient or abnormal protein, Ib) augment an existing 
pathway, Ic) provide a novel function or activity, IIa) interfere with a molecule or 
organism, and IIb) deliver and/or target a cargo. Groups III and IV are subdivided 
based on how the proteins are used as: vaccines against IIIa) deleterious foreign 







Figure 1. Classification of therapeutic proteins (adapted and modified from Leader et al., 2008). Examples of each 
subgroup have been given in boxes below the group definitions. 
2.1.4 The global therapeutic protein market
 
Aside from some ebb and flow in annual approval numbers, the rate of new biologicals 
appearing on the market has not shown signs of slowing. On the contrary, the share of 
biologicals among new active substances (NAS) to receive marketing approval from 
the US Food and Drug Administration (FDA) and European Medicines Agency 
(EMA) has been approximately 30% in recent years (EMA, 2016–2020; FDA, 2009, 




Figure 2. Approvals of new active substances. a) FDA2 2009-2020; data are from Drugs@FDA b) EMA 2015-
2018; data are from EMA, 2016–2020.  
2 Review of biologicals by FDA is divided between Center for Drug Evaluation and Research (CDER) 
and Center for Biologics Evaluation and Research (CBER) depending on the therapeutic class. For 
consistency, only CDER-regulated biopharmaceuticals, i.e., mAbs and therapeutic proteins, are 


























































































































The evidence indicates that these numbers are unlikely to go down; in 2013 over 400 
drugs in clinical trials or under FDA’s review were biologicals (PhRMA, 2013) and, 
in 2019, nearly 40% out of all NASs in the research and development (R&D) pipeline 
were biologicals (Pharmaprojects, 2019; Fig. 3). Although emerging (advanced) 
therapies, e.g., antisense, cell therapy and gene therapy, are in included in these 
numbers, mAbs and other proteins remain the most significant biopharmaceuticals 
(PhRMA, 2013; Lagassé et al., 2017; Morrison, 2018; Walsh, 2018; Table 1). 
Moreover, the expansion rate of new mAbs in the R&D pipeline has, in recent years, 
consistently surpassed that of small molecules and the overall average of the top-25 
followed drug categories (Pharmaprojects, 2015–2019; Fig. 4). 
 
Figure 3. Share of biopharmaceuticals in the Pharma R&D pipeline 1995-2018. Data from Pharmaprojects, 2019. 
Table 1. Share of pipeline drugs by origin. 
















Chemical, synthetic  56.4 56.0 55.8 53.7 52.2 51.9 
Biological, antibody 10.5 10.5 10.9 11.5 11.8 12.8 
Biological, recombinant protein 7.3 7.3 6.6 5.9 5.4 5.3 
Biological, protein 3.3 3.4 3.3 3.7 3.3 3.3 
Chemical, synthetic peptide 3.1 3.3 3.2 3.2 2.9 2.7 
 
 
Figure 4. Annual expansion rates of chosen chemical classes in the R&D pipeline 2014-2018. Data are from 
Pharmaprojects 2015–2019. 
In both 2017 and 2018, 7 out of the top 10 pharmaceuticals by global sales were 
































Urquhart, 2019). Furthermore, in 2024, 31 out of 50 globally top selling 
pharmaceuticals are expected to be biologicals (EvaluatePharma, 2018). Likewise, 
revenues are expected to remain high and in 2018, 10 out of 20 most valuable R&D 
projects were biologicals. Projections for the global therapeutic proteins market 
predict a compound annual growth rate (CAGR) of 10.6% and 9.4% p.a. up to 2019 
(BCC Research, 2015) and 2024 (Research and Markets, 2018), respectively. 
Furthermore, biotechnology products are predicted to reach a 31% market share and 
to represent 52% of the Top 100 drug sales by 2024, up from 25% and 49% in 2017, 
respectively, underlining the industry’s trust and commitment with biologicals as 
NASs (EvaluatePharma, 2018). 
Studies comparing the success rates and approval times of small molecules and 
biologicals in clinical trials have revealed that biologicals tend to fare better (Reichert, 
2003; Kola & Landis, 2004; DiMasi et al., 2010; Hay et al., 2014; Hwang et al., 2016; 
Smietana et al. 2016). However, despite intensive research, successful approvals, and 
thus somewhat warranted high expectations, biologicals have not been able to break 
the so-called Eroom’s law, the observation that in spite of technological 
advancements, drug discovery and development is getting increasingly more 
expensive yet yielding fewer new drugs (Scannell et al., 2012). While more resources 
are funneled to develop new drugs, nonetheless a smaller fraction of drugs succeed in 
clinical trials and eventually gain market access (Hay et al., 2014; Schuhmacher et al., 
2016). Despite the emergence and success of biologicals, R&D efficiency for 
biologicals is not markedly better (DiMasi et al., 2010) and the unsustainable trend 
remains undisrupted, calling for novel and innovative approaches to address the issue 
(Schuhmacher et al., 2016). Limitations and obstacles, such as long production times 
and high costs, can hamper and even prevent more widespread use of biological drugs; 
a prime example of emerging innovations and solutions to counteract this is the Open 
Insulin Project, an initiative for circumventing regulations and developing insulin 
production in a ‘do-it-yourself’ manner on a city, community, or even individual scale 
to make this increasingly costly drug more accessible (Gallegos et al., 2018). 
2.2 Life of trouble with therapeutic proteins 
2.2.1 Protein structure and folding 
Therapeutic proteins are proteins that are applied medically to diagnose, treat, prevent, 
and cure diseases. Proteins consist of up to 20 different proteinogenic L-amino acids 
linked together by peptide bonds (Nelson & Cox, 2008). A polypeptide chain is called 
the primary structure and can range significantly in length and amino acid content 
between different proteins (Fig. 5a). Therapeutic peptides are polypeptide chains and 
hence chemically related molecules, but as they generally have less than 50 amino 
acids and a molecular mass below 10 kDa, they are distinct in many aspects such as 
pharmacokinetics (Diao & Meibohm, 2013), and for these reasons are not discussed 
further in this thesis.  
The high complexity and functions of proteins do not solely stem from the 
simple polypeptide chains, but the higher-order conformations they fold into (Kessel 
& Ben-Tal, 2018). Interactions, such as hydrogen bonds, ionic bonds, and 




to fold into simple energetically favorable ordered conformations known as secondary 
structures, such as α-helices (Fig. 5b), β-sheets (Fig. 5c), and turns. Compacting of 
the secondary structures into motifs held together by aforementioned interactions, and 
further stabilized e.g. by interchain disulphide bridges, result in the tertiary structure 
(Fig. 5d). This native structure and its features give rise to functions and biological 
activities of proteins. Some proteins have a multimeric structure where individual 
tertiary structures oligomerize to quaternary structures (Fig. 5e). Moreover, many 
proteins also have one or more glycan moieties – polysaccharides comprised of 
various sugar molecules – attached to specific amino acids as integral parts of their 
structure in addition to other post-translational modifications (PTMs), adding yet 
another layer of structural complexity and heterogeneity (Goh & Ng, 2018). 
Despite several types of contributing interactions, the major overall driving 
force in protein folding and stabilization of the structure is considered to be the so-
called hydrophobic effect (Tanford, 1997; Chandler, 2005; Nelson & Cox, 2008; 
Compiani & Capriotti, 2013); the water molecules’ strong propensity to form and 
maintain hydrogen bonds leads to the burial of most non-polar, hydrophobic residues 
into the protein core – away from aqueous solvent – whereas polar residues remain 
exposed to solvent at the protein surface. 
Proteins’ attributes, e.g. molecular mass, hydrodynamic size, charge 
distribution, hydro- and lipophilicity, and other physico-chemical properties, play a 
role in their functions in the body and give rise to complex and heterogenous structures 
(Nelson & Cox, 2008; Kessel & Ben-Tal, 2018a) and their interactions in various 
complexes (Kessel & Ben-Tal, 2018b). It is not difficult to fathom why therapeutic 
proteins differ so much and in so many aspects from small-molecule drugs; a side-by-
side comparison already reveals the most obvious differences: size and structural 
complexity (Fig. 5f). The size difference between acetylsalicylic acid (Aspirin®), a 
small-molecule drug of 180 Da with a radius of approximately 0.5 nm, and a 
monoclonal antibody of 150,000 Da with a radius of 5.5-6.5 nm translates roughly to 
that between a green pea and a grapefruit. Other differences are discussed in following 












Figure 5. Structural features of proteins. a) Primary structure of tetrapeptide asparaginylisoleucyllysylisoleucine, 
b) α-helix, c) (anti-parallel) β-sheet, d) tertiary structure (a β-barrel monomer), and e) quaternary structure 
(tetramer of four β-barrels) of streptavidin. f) Size and structural complexity comparison between pembrolizumab 
(Mr=146,000 Da), an IgG protein therapeutic, and Aspirin (Mr=180 Da), a small-molecule drug. Images for 
Streptavidin (4GJS), Pembrolizumab (5DK3), and Aspirin® have been procured from The Research Collaborative 







Table 2. Comparison of small-molecule drugs vs. biologicals (adapted and modified from Morrow & Felcone, 
2004; Mahmood & Green, 2007; Schellekens, 2009; Shi, 2014; Andrews et al., 2015; Ferl et al., 2016; Oo & 
Kalbag, 2016; Wan, 2016). 







Molecular weight (Mr) < 1000 Da Up to 170,000 Da 
Drug substance Single entity; chemically pure Generally uniform;  related molecules/ fragments present 
Structure Simple, well-defined 
Complex (e.g., tertiary structure, PTMs), 
heterogenous, defined by manufacturing 
process 
Physicochemical 
properties Well-defined Complex, depends on the environment 
Physicochemical 
characterization Well-defined 
Full characterization is complex if not 
impossible 










ADME & tools Extensive ADME understanding,  tools available 
Understanding and tools of ADME still 
evolving 
Administration route All routes, per oral usually possible Parenterally as injections/infusions  (IV, SC, IM, IVT); per oral not feasible 
Absorption Rapid entry into systemic circulation via blood capillaries 
If not administered systemically, initial 
distribution via lymphatic system upon 
e.g. SC administration 
Distribution volume (Vd) 
Sometimes high Vd, variable,  
protein binding and transporters 
play a role, distribution to many 
organs/tissues/cells  
Lower Vd, distribution often limited to 













CYP P450 enzymes & phase II 
enzymes;  
active and non-active metabolites 
Proteases and peptidases ubiquitous in the 
body; catabolism to non-active peptides 
and single amino acids that are used de 
novo in protein synthesis 
Renal  Renal excretion 
Renal excretion possible for small 
proteins and fragments; enzymatic 
degradation  
Hepatic Metabolism, biliary excretion Non-specific proteases and peptidases 
Target-mediated Rare Yes 
Intestinal CYP P450 enzymes, transporters Not relevant due to parenteral administration 
Half-life (t1/2) Short; several hours to 24 h Long; days to weeks 
Clearance  Mostly linear, can be saturable Slow clearance 
Drug-drug interactions Common, both PK and/or PD related Less common; PD related 





Table 2 continued. 








Potency and selectivity Selective and non-selective  Highly potent and highly selective 
Target Varies, intracellular and CNS possible 
Membrane impermeable;  
targets extracellular and outside CNS 
Toxicity On- and off-target toxicity Low toxicity; mainly exaggerated pharmacology 
Immunogenicity Rarely observed Frequently observed;  often of clinical significance 
 
PK/PD 
Due to dominance of non-target 
binding,  
PK usually not driven by PD 
PK and PD mechanistically connected;  











Quantification LC-MS/MS methods Mostly ligand binding assays (ELISA);  recently LC-MS/MS 
Production 
Chemical synthesis,  
predictable and well defined,  
standardized and reproducible 
Manufactured in living cell cultures,  
up to 5000 critical process steps,  
batch-to-batch variation, engineering 
possible 
Formulation Complex, diverse Simple aqueous or freeze-dried formulations 
Species reactivity Multiple animal models relevant Many animal models irrelevant 
ADME, absorption, distribution, metabolism and elimination; CNS, central nervous system; ELISA, enzyme-
linked immunosorbent assay; IM, intramuscular; IV, intravenous; IVT, intravitreal; LC-MS/MS, liquid 
chromatography – tandem mass spectrometry; PD, pharmacodynamics; PK, pharmacokinetics; PTM, post-
translational modification; SC, subcutaneous. 
2.2.2 Stability of therapeutic proteins 
As large, complex, and flexible molecules, proteins are fragile and susceptible to 
external factors and stimuli (Morrow & Felcone, 2004). Compared to the unfolded 
state, the folded (native) state of proteins is energetically only marginally more 
favorable, and proteins remain chemically and physically stable only within narrow, 
protein-specific conditions and environments favoring this native state (Rathore & 
Rajan, 2008; Andrews et al., 2015). As the functionality, and therefore pharmaceutical 
activity, of therapeutic proteins is dependent on the intricate protein structure and the 
maintenance of this delicate three-dimensional conformation, therapeutic protein 
stability is of utmost importance (Radhakrishnan et al., 2017). 
The protein concentrations and milieus in which therapeutic proteins are handled 
and formulated in can be far removed from each protein’s ‘normal’, physiological 
conditions (Lipiäinen et al., 2015). Differences from the protein-specific optimal pH, 
temperature, and ionic strength as well as perturbations in these factors, along with 
stress from shear and contacts with interfaces, surfaces, and impurities during 
processing can all adversely affect therapeutic proteins (Frokjaer & Otzen, 2005; Patel 
et al., 2011; Gervasi et al., 2018). These different factors may interfere with a 
therapeutic protein’s chemical composition and/or its physical state (Manning et al., 
2010). For example, destruction and formation of chemical bonds can destabilize the 
protein structure and/or trigger proteins to unfold. Furthermore, as its 
biotransformation can impact efficacy, maintaining stability in the in vivo milieu after 




The numerous protein degradation pathways further complicate the picture; 
degradation may initiate via one pathway and proceed through other and even multiple 
pathways (Rathore & Rajan, 2008). Regardless of the degradation mechanisms and 
pathways, therapeutic protein instability can result in the alteration or even 
abolishment of the proteins’ functions, most commonly manifesting as loss of 
therapeutic efficacy and enhanced immunogenicity (Patel et al., 2011; Lipiäinen et al., 
2015; Nejadnik et al., 2018). Whereas protein degradation may be less detrimental 
and reversible in the short-term, irreversible degradation and irretrievable loss of 
protein structure often takes place, especially in the long-term. 
2.2.3 Production of therapeutic proteins  
Therapeutic protein engineering 
(Native) proteins fall short in many desirable and required features for optimal 
druggability, such as solubility, immunogenicity, biological half-life, etc. 
(Szymkowski, 2005; Dingermann, 2008). Therapeutic protein engineering is now 
commonly carried out to augment, incorporate and modify such pharmaceutical 
attributes and qualities. The currently available approaches and techniques are diverse, 
with certain strategies having gained a firm foothold.  
Fusion proteins are often constructed to extend the biological half-life, whereas 
a protein’s glycosylation pattern may be altered to influence receptor-binding 
(Lagassé et al., 2017) or, in the case of the glycoengineered erythropoietin 
darbepoetin-α, to increase the biological half-life (Dingermann, 2008). Similarly, 
PEGylation imparts protection against enzymatic degradation, diminishes 
immunogenicity and renal clearance by increasing a therapeutic protein’s size, which 
translates into extended circulatory half-life and improved protein stability 
(Szymkowski, 2005; Shi, 2014; Lagassé et al., 2017). Aside from such ‘extrinsic’ 
modifications, a protein itself and, for example, it’s primary sequence can be 
engineered to influence pharmacokinetics, ligand/receptor binding, stability, etc. 
Dramatic improvements in protein stability have been achieved with minimal amino 
acid changes in certain cytokines (Szymkowski, 2005), while pegvisomant is a human 
growth hormone variant engineered to compete with the endogenous protein, i.e., to 
act as a receptor antagonist (Dingermann, 2008). 
Upstream processing – therapeutic protein expression 
Therapeutic proteins are generally not amenable for production by chemical synthesis 
because of their large size and complexity, but instead need to be expressed as 
recombinant proteins in living cells with bacterial, mammalian, and yeast systems 
being the most commonly utilized (Lagassé et al., 2017; Ryman & Meibohm, 2017; 
Wells & Robinson, 2017). The required expression system, culture conditions, etc. are 
mostly dictated by the protein and its (possible) PTMs, such as glycosylation. 
Reflecting the high number of mAbs, approximately 70% of recombinant therapeutic 
proteins on the market are produced in glycosylation-performing mammalian-based 
systems, such as Chinese hamster ovary (CHO) cells (Stech & Kubick, 2015), whereas 




In recent years, there has been increased interest in cell-free protein synthesis 
(CFPS) based platforms for therapeutic protein production (Zawada et al., 2011; Lee 
& Kim, 2018; Khambhati et al., 2019). These in vitro systems can be derived from 
both prokaryotic and eukaryotic cells and offer notable advantages in contrast to 
traditional, living cell-based protein expression systems. For example, the cytotoxicity 
of expressed protein is not a limiting factor as cell maintenance is not needed, allowing 
for the expression of toxic proteins and other ‘difficult-to-express’ proteins. The 
system’s openness – the cell lysis has taken place before protein production – allows 
the protein synthesis conditions to be more tightly controlled, and the capacity and 
resources to be focused toward target protein production. The open nature of these 
systems also enables the incorporation of unnatural amino acids, which can in turn be 
utilized, e.g., in protein engineering and bioconjugation (Casteleijn et al., 2013; Stech 
et al., 2014; Khambhati et al., 2019). Moreover, CFPS systems can utilize linear DNA 
templates, allowing for streamlined parallel expression of various proteins, effectively 
shortening the production times from weeks and months to mere days (Stech & 
Kubick, 2015; Lee & Kim, 2018). Different CFPS systems have so far been utilized 
in the small-scale production of many therapeutic proteins, such as erythropoietin 
(Sullivan et al., 2016), antibody fragments (Stech et al., 2014) and full antibodies 
(Buntru et al., 2015; Stech et al., 2017). 
Although the industrial-scale production of biologicals using CFPS technologies 
is still in its infancy, Sutro Biopharma, for example, has utilized their E. coli-based 
platform to produce an active cytokine at a 100-liter scale with yields comparable to 
more established, living cell-based platforms (Zawada et al., 2011). The potential of 
these technologies is substantial, and they can be envisioned to be applied in the point-
of-care production of niche biologicals – therapeutics for orphan diseases or patient-
specific treatments – that do not require large batch sizes (Sullivan et al., 2016; Timm 
et al., 2016; Ogonah et al., 2017). Broader possibilities can be expected to arise with 
technological advancements, as for example tight control of target protein 
glycosylation has recently been achieved in E. coli based CFPS for the first time 
(Jaroentomeechai et al., 2018). 
Downstream processing – therapeutic protein processing and formulation 
Regardless of utilized expression systems, after production, proteins are commonly 
subjected to several steps of protein purification and evaluation before a therapeutic 
protein is finally formulated into a finished drug product (Lagassé et al., 2017; Wells 
& Robinson, 2017). The instability of proteins makes their pharmaceutical 
development and manufacture complex and often challenging. Proteins may be 
susceptible to changes in the manufacturing steps and the involved processes must be 
meticulously optimized and strictly controlled to minimize batch-to-batch variation in 
the finished drug products (Crommelin et al., 2005; Rathore & Rajan, 2008; 
Schellekens, 2009; Ryman & Meibohm 2017). Due to the manufacturing stages 
influencing the end-product and its quality, insofar that in therapeutic protein 
manufacturing the process itself is considered to ‘be’ the product (Baumann, 2006). 
Moreover, further complicating their manufacture is the fact that proteins are highly 
heterogenous and as each protein can be considered somewhat unique, production 




necessitating unique approaches and solutions (Andrews et al., 2015; Wells & 
Robinson, 2017). Large size together with structural complexity and heterogeneity 
tends to translate into more challenges. Factors other than the protein itself can also 
dictate the formulation requirements. For example, with IVT injections high doses are 
often needed for therapeutic efficacy and as the FDA limits the maximal injectable 
volume, therapeutic proteins for IVT administration need to be formulated at very high 
concentrations, which are in turn, often highly viscous and thus poorly syringeable 
(Mandal et al., 2018). Likewise, the excipients approved for intravitreal injections are 
very limited, thereby constraining stabilization possibilities (Wakshull et al., 2017). 
As already discussed, therapeutic proteins are susceptible to many destabilizing 
external stimuli and they can degrade through numerous different pathways (Manning 
et al., 1989; Patel et al., 2011). Hence, proteins require protection through stabilization 
– especially in the case of unmodified native proteins – to ensure therapeutic efficacy 
and safety, and to retain product integrity (Szymkowski, 2005; Radhakrishnan et al., 
2017). As different process-stresses can potentially impact the efficacy and activity of 
therapeutic proteins, careful control of process parameters is required to alleviate these 
concerns (Rathore & Rajan, 2008).  
Therapeutic protein formulation aims to identify a final pharmaceutical 
composition in which the protein remains stable and resistant towards the stresses 
during manufacturing, storage, and administration (Frokjaer & Otzen, 2005; Gervasi 
et al., 2018). Common therapeutic protein formulation and stabilization strategies 
include the optimization of buffer, pH, and osmolarity as well the inclusion of 
stabilizing excipients, such as chelating agents, detergents, polymers, surfactants, 
sugars and polyols, as well as free amino acids (Frokjaer & Otzen, 2005; Szymkowski, 
2005; Jorgensen et al., 2009; Manning et al., 2010; Gervasi et al., 2018). As 
mentioned, therapeutic protein engineering can be carried out to enhance stability; 
PEGylation, i.e., conjugating polyethylene glycol (PEG), and glycoengineering can 
improve protein stability whereas modifying the protein itself via, e.g., site-directed 
mutagenesis, has been utilized to improve both the chemical and physical stability of 
therapeutic proteins. After release, product (mis)handling – either in a hospital setting 
or by the patient – can still expose therapeutic proteins to various stresses that may 
compromise therapeutic protein stability, and the safety and efficacy thereafter 
(Nejadnik et al., 2018). Clearly, maintaining stability is of paramount importance in 
all stages of a biological’s lifetime. 
However, the different mechanisms of stabilization are not comprehensively 
resolved and may in fact differ between individual therapeutic proteins. Hence, 
although certain strategies and technologies have become somewhat standard, it needs 
to be noted that currently there is no catch-all approach capable of universally 
resolving therapeutic protein stability challenges, and that formulation development 
must be based on understanding each individual protein’s unique requirements and 





2.2.4 Systemic pharmacokinetics and administration of therapeutic proteins 
Since the subject of therapeutic protein pharmacokinetics (PK) is broad, the following 
is a very limited summary in which some omissions and overt generalizations are 
unavoidable. Key aspects are also presented in Table 2. 
Therapeutic proteins’ PK differs considerably from that of small-molecule 
drugs’ in most aspects of drug disposition, i.e., absorption, distribution, metabolism 
and elimination (ADME), as the involved mechanisms and pathways differ (Lin, 
2009). Most of these differences can be attributed to protein properties, perhaps most 
importantly their high molecular weight and size, and susceptibility to degradation 
owing to their biological origin (Mitragotri et al., 2014). Due to the former, therapeutic 
proteins do not readily permeate through biological membranes, such as cell 
membranes and mucous membranes, a feature in and of itself a significant determinant 
of their PK. 
Absorption and distribution 
Intestinal digestive enzymes break protein consumed in food down into smaller 
peptides and amino acids before their absorption from the gut lumen to the circulation. 
Per os administered therapeutic proteins are not an exception: they are unstable in this 
hostile proteolytic environment and cannot penetrate the epithelium of the gut, 
resulting in poor bioavailability and practically nullifying the use the oral 
administration route. However, given the associated advantages such as non-
invasiveness, ease of dosing and high patient compliance, its realization is nonetheless 
considered the ‘holy grail’ of therapeutic protein dosing and different means – ranging 
from the engineering, conjugation, and chemical modification of therapeutic proteins 
to their encapsulation in micro- and nanoparticle drug delivery systems –  to achieve 
this are continually explored (Shen, 2003; Patel et al., 2014; Shah, 2015). 
Currently, to attain adequate systemic exposure therapeutic proteins are 
administered parenterally as injections or infusions via intravenous (IV), 
intramuscular (IM) and subcutaneous (SC) routes, or for local effect, e.g., as IVT 
injections (Vugmeyster et al., 2012; Shah, 2015). Although direct systemic delivery, 
avoiding pre-systemic degradation, is possible with IV administration, this may not 
provide the ideal concentration-time profile and is impractical (Tang et al., 2004). 
While the SC route is suitable for self-administration and allows larger injection 
volumes, the bioavailability upon IM and SC administration may be limited, for 
example, by local blood flow and on-site enzymatic degradation (Wang et al., 2008; 
Vugmeyster et al., 2012; Shah, 2015). Both IM and SC administered biologicals 
absorb slowly, entering the circulation via convection through lymphatic vessels and 
by diffusing into capillaries at and near the injection site, the former being more 
dominant with high Mr biologicals (Tang et al., 2004). 
Absorption via other parenteral routes is also possible and many biologicals 
have been shown to successfully enter circulation upon, for example, nasal and 
pulmonary administrations (Patel et al., 2014). Nasal administration of biologicals is 
of interest as by circumventing the blood-brain barrier (BBB) it may, for example, 
allow for the successful central nervous system (CNS) delivery of neurotrophic factors 
to treat neurodegenerative diseases (Thorne & Frey, 2001; Yi et al., 2014). Whereas 




this administration route (Thorne & Frey, 2001; Vaka et al., 2009), intranasally 
administered biologicals have nonetheless been documented to reach higher CNS 
concentrations than upon IV administration, and to elicit pharmacological actions 
(Thorne & Frey, 2001; Hong et al., 2019). While pulmonary delivery offers 
convenient delivery to a site with a large, highly vascularized surface area available 
for absorption, there are plenty of obstacles such as local enzymatic activity in the 
alveoles, potential for local effects of inhaled therapeutics/excipients, and 
considerable formulation challenges that complicate the development of inhalable 
biologicals (Tang et al., 2004). This has nonetheless been achieved with inhalable 
formulations for the treatment of cystic fibrosis and diabetes, and many therapeutic 
protein products for pulmonary delivery are currently in development (Morales et al., 
2017). 
Owing to poor membrane permeability, the tissue distribution of biologicals is 
limited and generally restricted to the plasma and the interstitial compartment. In 
addition to protein properties such as molecular size, charge, target and off-target 
binding, the administration route as well as tissue physiology also contribute to protein 
biodistribution (Vugmeyster et al., 2010; Shah, 2015). Aside from therapeutic protein 
size and charge, extravasation to tissues also depends on vascular porosity and takes 
place mostly via convection and to a lesser extent via diffusion. Other mechanisms 
such as FcRn-mediated transcytosis, active tissue uptake, and binding to carrier and 
transport proteins can influence distribution of certain biologicals (Tang et al., 2004; 
Baumann, 2006; Lin, 2009). However, poor tissue distribution does not necessarily 
paint the full picture; as e.g. mAbs that have their putative targets in tissues can, 
regardless of limited tissue distribution, show that the limited tissue penetration can 
be sufficient for therapeutic efficacy (Vugmeyster et al., 2012). 
Biologicals have so far been predominantly used against extracellular or cell-
surface targets, and excluded from intracellular targets (Mitragotri et al., 2014). 
Although therapeutic protein entry to cells is hampered by poor permeation through 
cell membranes, an even more formidable obstacle is that the internalized proteins are 
often not free in the cytosol. Instead they are trapped in vesicular structures and 
commonly destined for degradation processes, effectively preventing them from 
reaching their cytosolic targets (Fu et al., 2014). On a similar note, the physiology of 
the intact BBB effectively obstructs the penetration of biologicals to the CNS (Thorne 
& Frey 2001). Accordingly, successful CNS and intracellular targeting of therapeutic 
proteins will require creative and sophisticated solutions and while varied approaches 
have been explored – some even in clinical trials – to date none have yet entered the 
clinic (Dinca et al., 2016; Fu et al., 2014; Yi et al., 2014; Guillard et al., 2015). 
Metabolism and elimination 
Therapeutic proteins are broken down via the same pathways as endogenous proteins, 
i.e., enzymatically by proteases and peptidases in various organs and tissues. 
Depending on a therapeutic proteins’ properties, this proteolysis can take place in 
locations including the liver, kidneys, blood, as well as locally at administration sites 
(Tang et al., 2004). Therapeutic protein properties and their physiological roles are 
mirrored by their clearance; protein hormones are naturally short-lived as this allows 




a significantly longer sojourn in the body since their action over longer periods of time 
is warranted. Hence, the pathways of metabolism and elimination of biologicals can 
largely be protein dependent. 
Although the renal excretion elimination route is considered an important 
elimination pathway for many small-molecule drugs and their (active) metabolites, 
when considering therapeutic proteins and their degradation products, most often the 
excretion of unchanged protein into the urine is negligible (Baumann, 2006, 
Vugmeyster et al., 2012). Glomerular filtration is selective on protein size, structure 
and charge. While proteins and degradation products smaller than the cut-off value for 
retinal filtration (60 kDa), and in particular biologicals smaller than 30 kDa can be 
eliminated by excretion into the renal tubules, the major degradation pathway is 
nonetheless via enzymatic proteolysis in the nephrons after glomerular filtration (Lin, 
2009; Vugmeyster et al., 2012). 
Clearance can also take place via the liver. Biologicals can be taken up into 
hepatic cells, e.g., via pinocytosis and receptor-mediated transport processes and 
subjected to intracellular enzymatic elimination (Baumann, 2006). For example, 
certain glycoprotein receptors, such as lectins expressed on hepatocytes and hepatic 
endothelial cells are responsible for recognition and internalization of glycosylated 
proteins and may therefore significantly contribute to their clearance (Lin, 2009). 
Proteins can also be transported through the cells and into bile. Although e.g. IgA-
class antibodies are known to be excreted into bile and later into the GI tract, this 
pathway of elimination is considered negligible for most biologicals.  
Finally, the target-mediated drug disposition (TMDD) can play a significant 
role. Upon binding to cell-surface targets such as receptors, biologicals can trigger 
their endocytosis and subsequent intracellular degradation in lysosomes (Vugmeyster 
et al., 2012). Depending on the physiological distribution of targets, TMDD can be a 
major elimination step for some biologicals. As it shows how distributing to targets 
(both on- and off-) to elicit pharmacodynamic effects can be considered an elimination 
step, it is a prime example of how difficult drawing a line between different ADME 
events of biologicals can be. Since the number of targets can be limited, this 
elimination pathway may be saturated even with therapeutic drug concentrations, 
giving rise to non-linear PK with many biologicals. 
Fc receptor binding 
The Fc domain in antibodies and biologicals (e.g. mAbs; Fig. 6a and engineered Fc-
fusion proteins) and the plasma protein albumin is recognized by Fc receptors and 
complement proteins. While antibody binding to Fc receptors serves biological 
purposes such as transporting IgGs across the placenta, inducing phagocytosis and 
microbe killing, it has implications on the PK of both albumin- and Fc-containing 
biologicals (Sockolosky & Szoka, 2015; Schmidt et al., 2017). Fc-gamma receptors 
(FcγR) are expressed on the surface of certain phagocytic cells, such as macrophages, 
and can trigger the intake and subsequent lysosomal degradation of bound proteins 
(Vugmeyster et al., 2012). The contribution of this pathway of clearance is, however, 
considered of little significance to many biologicals, as their amounts are often small 
compared to endogenous antibodies. In fact, only a very small fraction of the full 




susceptible to clearance via this route (Liu, 2018). Its role cannot however be 











Figure 6. a) Schematic diagram of antibody structure and regions. Fv, fragment, variable; Fab, fragment, antigen-
binding; Fc, fragment, crystallizable; FcRn, neonatal Fc receptor. b) Model of FcRn’s involvement in the 
transcytosis, and the recycling of albumin and IgGs. Proteins are internalized by pinocytosis or endocytosis (I) 
and as they are transported along the endosomal pathway, the acidification in the early endosomes results in 
association with the endosomal FcRn (II). As FcRn-protein complexes and unbound proteins are sorted (III), the 
FcRn-bound proteins evade lysosomal degradation and are recycled back to the cell membrane and liberated due 
to low affinity at physiological pH (IV) while unbound proteins are sorted for degradation in the lysosomes (V). In 
polarized cells the FcRn-mediated transcytosis can direct the FcRn-protein complexes directed to opposing cell 
membranes, where protein release takes place at physiological pH (VI). Adapted and modified from Roopenian & 
Akilesh, 2007. 
Unlike with FcγR, binding to the neonatal Fc receptor (FcRn) can significantly impact 
the PK of biologicals. A major determinant of the binding is its pH dependency; 
binding to FcRn is negligible at physiological pH but is significantly more pronounced 
in acidic pH (Roopenian & Akilesh, 2007). While the association between FcRn and 
Fc fragment is pH-dependent and a prerequisite for the interaction, more distal regions 
can also affect this interaction (Wang et al., 2011; Jensen et al., 2015; Monnet et al., 
2015). It has been recently demonstrated that, e.g., the electrostatic charge of the Fv 
region of the Fab domain influences the interaction (Schoch et al., 2015; Ternant et 
al., 2016) and that even very small changes, especially in the complementarity-
defining region, can have profound effects on the FcRn binding affinity and thus PK 
of IgGs (Piche-Nicholas et al., 2018). Furthermore, the impact of regions distal to the 
Fc domain are evident in the case of Fc-fusion proteins, as they have been shown to 
exhibit lower binding affinity to FcRn due to the fusion partner (Liu, 2015). 
Elucidating the molecular basis of FcRn-binding has shed light on the key 
contributors, i.e., epitopes and residues responsible for the interaction, and will 
undoubtedly guide the rational design of engineered proteins (Oganesyan et al., 2014; 
Jensen et al., 2015; Monnet et al., 2015; Sockolosky & Szoka, 2015). 
While other factors may influence the binding, their impact on the PK might not 
be clinically relevant. For example, glycosylation and lack thereof, can have 
widespread influence on the conformation, function, stability, immunogenicity and 




demonstrated to be sensitive to IgG glycosylation in vitro, possibly due to altered 
binding dynamics, this does not seem to translate to changes regarding the in vivo PK 
(Liu et al., 2011; Jensen et al., 2015; Liu, 2015).  
FcRn expression is widespread in the body (Pyzik et al., 2015; Latvala et al., 
2017), localized mostly in intracellular vesicles, such as endosomes, and to a lesser 
extent on cell surfaces (Sockolosky & Szoka, 2015). Proteins in circulation are thus 
thought to be continuously removed mostly through non-specific, fluid-phase 
pinocytosis and less through receptor-mediated endocytosis (Pyzik et al., 2015; Liu, 
2018; Fig. 6b: I). Therefore, proteins mostly encounter FcRn in the early endosomes, 
where upon acidification of the internalized proteins’ milieu, association with the 
FcRn takes place (Fig. 6b: II). After sorting, the FcRn-bound proteins avoid lysosomal 
degradation (Fig. 6b: III) and migrate to the cell surface where the FcRn-complexes 
are dissociated in the physiological pH milieu, thereby releasing the proteins (Fig. 6b: 
IV), whereas unbound proteins are sorted for lysosomal degradation (Fig. 6b: V). 
Furthermore, the FcRn-protein complexes can also be trafficked to opposing cell 
membranes in polarized cells, such as endothelial cells, and then released due to 
neutral pH (Fig. 6b: VI). This FcRn-mediated transcytosis of proteins is recognized 
as a mechanism for, e.g., transporting IgGs from the alveoles to systemic circulation, 
and through the placenta from mother to fetus (Roopenian & Akilesh, 2007).  
FcRn-mediated recycling can salvage IgGs and albumin from intracellular 
clearance and is the main reason why their circulatory half-lives are notably longer 
compared to other proteins. As such, the impact of binding to FcRn on Fc-containing 
biologicals’ PK is an extended half-life (Shah, 2015). The effect is not only at the 
systemic level; the local effects of FcRn in different cells and tissues are becoming 
more evident as its expression is mapped (Latvala et al., 2017; Deissler et al., 2017; 
Deissler et al., 2018). FcRn’s possible role in tissue distribution of biologicals is, 
however, still under debate as all aspects are not yet fully understood (Kamath, 2016; 
Shah, 2015). While some report FcRn to have a negligible role in tissue distribution, 
others have demonstrated FcRn to play a role in the distribution and tissue selectivity 
of biologicals (Garg & Balthasar, 2007; Chen et al., 2014; Ryman & Meibohm, 2017). 
Different methodologies, such as physiology-based pharmacokinetic modeling (Ferl 
et al., 2005; Garg & Balthasar 2007) and both FcRn knock-out (Chen et al., 2014) and 
humanized FcRn mouse models (Proetzel & Roopenian, 2014; Avery et al., 2016) 
have been utilized to elucidate FcRn’s contribution to the PK of Fc-containing 
biologicals and to see how modulating this interaction can be utilized in protein (PK) 
engineering. 
2.2.5 Immunogenicity of therapeutic proteins 
Therapeutic proteins have a ‘self’ origin and as such they have little intrinsic toxicity 
and subsequently rarely cause adverse effects per se as they manifest mainly as 
exaggerated pharmacology (Schellekens, 2010). However, the biggest limitation in 
their use is that therapeutic proteins are commonly observed to elicit immune 
responses in patients, i.e., being immunogenic (Descotes & Gouraud, 2008). The 
immune system can recognize attributes, such as deviations from the native sequence, 
presence of ‘non-self’ regions/sequences on the protein, certain epitopes (intrinsic, 




as glycosylation, and protein aggregates as threatful xenogenic entities that trigger 
subsequent immune responses (Descotes & Gouraud, 2008; Wadhwa et al., 2015; 
Kuriakose et al., 2016; Ryman & Meibohm, 2017). Thus, for example, fusion proteins 
and proteins with mutated sequences, and hence new epitopes, can potentially be more 
immunogenic than native proteins. Other non-protein factors include, i.a., concomitant 
therapies, underlying diseases and the route of administration (Schellekens, 2010, 
Wakshull et al., 2017). 
Immunogenicity is a feature of practically all therapeutic proteins. Humanized 
and even fully human proteins have been shown to induce immune responses, e.g. via 
protein aggregates (Descotes & Gouraud, 2008; Forooghian et al., 2009; Schellekens, 
2010; Deehan et al., 2015; Ryman & Meibohm, 2017). The specific triggers leading 
to an immune response vary, and the resulting complex coordinated events can involve 
the recruitment of components of both the adaptive and non-adaptive immune systems 
(Baker et al., 2010; Deehan et al., 2015; Wadhwa et al., 2015). 
Clinical outcomes of therapeutic protein immunogenicity differ. Anti-drug 
antibodies (ADA), i.e. specific antibodies formed against a (protein) therapeutic or a 
part of it, can have wide-ranging repercussions on patients. While immune responses 
frequently lead to only minor pathologies, such as a mild rash, or are completely 
asymptomatic (Descotes & Gouraud, 2008; Büttel et al., 2011; Smith et al., 2016), in 
rare cases neutralizing ADAs against therapeutic proteins can cross-react with 
homologous endogenous proteins, leading to their neutralization and subsequent 
severe, sometimes even fatal, outcomes (Baker et al., 2010; Deehan et al., 2015; Smith 
et al., 2016). Fortunately, only a small fraction of patients exhibits undesirable 
immune responses to biologicals (Kuriakose et al., 2016). 
Arguably the biggest impact protein therapeutics elicit via immunogenicity is 
upon themselves. Due to altered clearance of the affected proteins, subsequent 
perturbations in their pharmacokinetics and pharmacodynamics occur, mainly 
manifesting as a lowered efficacy (Smith et al., 2016). The main reasons for halting 
drug development projects in clinical trial phases II and III are lack of efficacy, safety, 
and commercial/strategical reasons (Kola & Landis, 2004; Arrowsmith & Miller, 
2013). Although safety is less of an issue and a reason for clinical trial discontinuations 
with therapeutic proteins, lack of efficacy is a frequent hurdle (Hwang et al., 2016; 
Patel et al., 2017). Since protein immunogenicity is often the root cause for lowered 
efficacy, and at times also a cause for clinical trial failures (Schellekens, 2010), this 
highlights the impact it can have on these drugs. To make matters even more 
complicated, although evaluating therapeutic protein immunogenicity and its clinical 
significance during drug development is required by regulatory authorities, for 
example in the European Union and the US (EMA, 2017b; FDA, 2014b), it is highly 
complex and much of the current methodology is not adequate (Wadhwa et al., 2015). 
For example, immunogenicity evaluation based on protein structure as well as on most 
in vivo animal models is regarded to be of poor predictive value and thus, unreliable 
(Deehan, et al., 2015; Smith et al., 2016). Likewise, assessing the local 
immunogenicity of biologicals, e.g., in the eye, is complicated (Wakshull et al., 2017, 
Wessels et al., 2018). Therefore, immunogenicity is frequently under-observed during 
pre-clinical development, becoming evident later in clinical trials or even after years 
of use in patients. This makes the impact – not only clinical but also financial – of 





To recap, biologicals are complex and delicate molecules and thus challenging to 
produce and handle. On the other hand, compared to traditional small-molecule drugs, 
biologicals are superior in specificity and elicit fewer adverse effects. From the launch 
of Humulin® the use of biologicals has since expanded to diverse fields of medicine. 
Ophthalmology is a field that has seen revolutionary changes with the introduction of 
biologicals and is at the focus of the following sections of this review. 
2.3 The human eye and ocular pharmacotherapy 
The eye is a highly complex and specialized organ, not only in its function but also in 
its physiology (Fig. 7a). Anatomically and for drug delivery, the human eye can be 
divided into anterior and posterior segments, separated by the anterior hyaloid 
membrane. The anterior segment makes up roughly a third of the eye and consists of 
the cornea, conjunctiva, iris, ciliary body and the lens, whereas the posterior segment 
contains the vitreous humor, choroid, retina and optic nerve (Awwad et al., 2017). The 
tissues of the anterior segment are responsible for focusing and adjusting the amount 
of light entering the eye, while the conversion of light stimulus to neural signals takes 
place in the posterior segment and more specifically in the specialized cells of the 





Figure 7. Schematic diagram of the human eye. a) Anatomical features of the eye, b) selected ocular administration 
routes: topical (I), intravitreal (II), and systemic (III). 
2.3.1 Ocular pharmacokinetics and administration of therapeutic proteins 
The physiology of the eye itself complicates the treatment of posterior segment 
diseases. Whereas ocular barriers are in place to, for example, prevent pathogen 
access, they also complicate and prevent the delivery of drugs, including biologicals, 
into the eye. For brevity, only the factors deemed most important are discussed here 
and the reader is directed to recent reviews for a more in-depth analysis of ocular 
pharmacokinetics and limitations therein (del Amo et al., 2017; Awwad et al., 2017; 
Huang et al., 2018). Furthermore, although the following sections in this thesis discuss 
ocular pharmacokinetics of biologicals in the intact eye, it should be noted that ocular 




Topical administration (Fig. 7b: I) of eye drops or other dosage forms (e.g. gels), 
usually by the patients themselves, is the least invasive and most logical way of 
administering drugs for treating the anterior segment (Wakshull et al., 2017). It is, 
nonetheless, complicated by several factors: the corneal epithelium is tightly packed 
and thus limits permeation, while residence time after administration is reduced by 
blinking, nasolachrymal drainage and tear film turnover, which is often increased due 
to irritation from the applied drug. Even after a minuscule fraction (< 5%) of a 
topically administered drug manages to permeate into the anterior chamber, the 
direction of aqueous humor flow and blood flow of the iris hampers efficient drug 
distribution past the anterior segment and towards the posterior segment. Low ocular 
bioavailability and clearance from the anterior chamber result in low drug 
concentrations in the eye. Therefore, topical administration of small molecule drugs 
is used only for treating the anterior segment and not the posterior segment of the eye 
(Ranta & Urtti, 2006; Patel et al., 2013), whereas biologicals are not used at all as 
topical ocular medications.  
Barriers do not only protect the eye from the outside, but also from within the 
body, as access to the eye from blood circulation is limited by the anterior blood-
aqueous barrier (BAB) and the posterior blood-retinal barrier (BRB). These barriers 
also complicate ocular pharmacotherapy. BAB has two components: endothelium in 
the iridial and ciliary muscle capillaries, and tight epithelia in the posterior iris and 
ciliary body (del Amo et al., 2017). The BRB consists of the inner BRB formed by 
endothelia of the retinal capillaries, and the outer BRB formed by the retinal pigment 
epithelium (RPE) cells that, for example, provide metabolic and nutritional support to 
the overlaying photoreceptors (Cunha-Vaz et al., 2011; Dwyer et al., 2011). Both are 
cellular monolayers with intercellular tight junctions that regulate the permeability of 
ions, nutrients, proteins and drugs. Whereas smaller molecules can penetrate both 
blood-ocular barriers, the permeation of biologicals and other macromolecules is 
effectively stymied mostly due to their large size (El Sanharawi et al., 2010). The 
permeability of the RPE can be altered due to ageing and in certain pathological 
conditions, allowing biologicals in the systemic circulation to enter the eye (Fig. 7b: 
III). Interestingly, several publications report clinical improvements in wet AMD 
patients receiving systemic bevacizumab (Michels, et al., 2005; Moshfeghi et al., 
2006; Bolz et al., 2007; Schmid-Kubista et al., 2009). However, these studies were 
conducted with limited number of patients over relatively short time periods ranging 
from 3 to 6 months. Whereas they do not report any serious adverse events and thus 
attest for short-term safety, they do not rule out possible complications associated with 
long-term systemic bevacizumab administration. Moreover, as these studies did not 
assess neither aqueous nor vitreal levels of bevacizumab, the underlying mechanism 
of ocular entry remains somewhat nebulous; entry via an anterior (Bakri et al., 2007a) 
and/or a posterior route (Magdelaine-Beuzelin et al., 2010) have been suggested. 
Additionally, it is unclear whether the clinical improvements arise from effects on the 
choroidal vessels only (El Sanharawi et al., 2010). Hence, to confirm safety and 
efficacy, more rigorous long-term clinical studies would be required, but this is 
unlikely as IVT injections (Fig. 7b: II) are more efficacious and perceived to be safer 
than intravenous injections (Moshfeghi et al., 2006). In conclusion, although the 
ocular entry of biologicals via the systemic circulation is possible and even 




generally considered unfeasible. The systemic doses required for reaching therapeutic 
concentrations inside the eye may be disproportionally high and likely to elicit 
systemic toxicity, limiting the applicability to only carefully screened patients, if not 
preventing it altogether (Moshfeghi et al., 2006; Schmid-Kubista et al., 2009; El 
Sanharawi et al., 2010; del Amo et al., 2017). 
The most direct means to circumvent these obstacles in treating vitreo-retinal 
diseases is by delivering drugs via injections, for example as subconjunctivally 
between the conjunctiva and the sclera or directly in the vitreous as IVT (Fig. 7b: II) 
(Delplace et al., 2015). Although other injection sites and techniques are possible, the 
IVT injection through the pars plana region has become the method of choice due to 
certain considerable advantages. Compared to other injection routes and their inherent 
limitations such as limited injection volume and poor bioavailability, IVT injections 
result in maximal intraocular bioavailability and effective local drug concentrations in 
the vitreous, retina and choroid with a reduced dose and minimal systemic side effects 
(Agrahari et al., 2017; del Amo et al., 2017; Iyer et al., 2019). The drawbacks of this 
dosing method are, on the other hand noteworthy: as it must be performed by trained 
medical professionals it is costly, and patients comply poorly as the administration can 
be uncomfortable and even traumatic (Moreno et al., 2016). The intravitreal half-lives 
of the administered biologicals – in the range of several days – requires dosing as 
frequently as every month, and as many compounds have even shorter intravitreal 
half-lives, they are not clinically acceptable for IVT dosing as they would necessitate 
even more frequent administration (del Amo et al., 2017; Lau et al., 2018). Clinical 
trials for comparing different IVT treatments and treatment regimens have been 
carried out (Awwad et al., 2017). For example, instead of treating based on 
patient/disease status, adhering to a more rigid treatment frequency was recently 
shown to correlate with superior treatment outcomes (Wecker et al., 2019). Yet, there 
appears to be no clear consensus on optimal treatment regimens among clinicians; 
ophthalmologists often deviate from those recommended while patients can fail to 
comply, hence the injections are commonly given at longer and possibly 
therapeutically less optimal intervals (Ferreira et al., 2015; Lanzetta et al., 2017). 
Furthermore, with every injection there is the possibility of complications and a small 
but nevertheless real risk of endophtalmitis (Awwad et al., 2017), a sight-threatening 
condition requiring immediate medical attention. Active pursuits to alleviate these 
burdens on both the patients and physicians are ongoing. Likewise, there are numerous 
endeavors in the global research and scientific community to develop new therapies 
and to improve and enhance available therapies. 
Administered biologicals distribute in the vitreous largely by diffusion (del Amo 
et al., 2017). The transparent vitreous consists mostly of water and has a gel-like 
structure maintained by a collagen fibril network with anionic glycosaminoglycans 
such as hyaluronic acid (HA) contributing to the gel viscosity (Meral & Bilgili, 2011; 
Käsdorf et al., 2015; Patel et al., 2015). This composition is not homogenous and 
changes as the vitreous undergoes liquefaction during aging. The vitreal diffusion of 
very large particles is restricted by the collagen fibrils, and the diffusion of cationic 
smaller species is suppressed by the anionic charges in the biopolymer network (Xu 
et al., 2013; Käsdorf et al., 2015). Therefore, overall diffusion restrictions to smaller 
neutral and anionic species are minor. However, it remains unclear whether the anionic 




significance (del Amo et al., 2017). Nevertheless, vitreal diffusion is not considered 
to impede the diffusion of biologicals to the retina, as observed with a porcine ex vivo 
model with heat shock protein 70 (Subrizi et al., 2014). Yet, more specific interactions 
with vitreal components may retard the vitreal diffusion of biologicals and could hence 
be utilized for extending their vitreal half-lives (Fuchs & Igney, 2017; Ghosh et al., 
2017; Rimpelä et al., 2018). 
Upon intravitreal administration, biologicals are abruptly subjected to a new, 
possibly destabilizing environment; the stabilizing formulation components are 
effectively and swiftly diluted in the vitreous and thus cease providing stabilization to 
the proteins (Patel et al., 2015; del Amo et al., 2017). Unprotected exposure to the 
physiological temperature, proteolytic enzymes and other vitreal components may 
have a destabilizing effect on biologicals, potentially leading to degradation and 
aggregation during the residence time in the vitreous (Patel et al., 2015; Patel et al., 
2017). Due to challenges associated with collection of clinical samples, the vitreal 
stability of therapeutic proteins is understudied and instead carried out with surrogate 
models. For example, in a study utilizing ex vivo porcine vitreous model, shifts in pH 
were observed to destabilize proteins (Patel et al., 2015). Conversely, the buffering 
capacity of sampled human vitreous was demonstrated to resist pH shifts and even 
maintain a stable pH upon administration of clinically used doses of anti-vascular 
endothelial growth factor (VEGF) biologicals (Sobolewska et al., 2017). Although 
this was postulated to reflect the in vivo stability, it is nonetheless possible that current 
ex vivo and animal models do not accurately represent the in vivo situation in human 
eyes. Recently, a more practical and feasible approach was described as the in vivo 
stability of IVT injected lampalizumab and its variants was evaluated using aqueous 
humor samples collected from patients (Loyet et al., 2019). Nonetheless, although the 
eye is commonly described as an immune privileged organ, as local immune responses 
to IVT administered biologicals have been reported (Wessels et al., 2018), it clearly 
is not immune incompetent. Therefore, it is possible, although not yet established, that 
protein destabilization and unfolding contribute to local immunogenicity after IVT 
administration. Clearly, many questions still need answers before reaching a 
comprehensive understanding of the influencing factors and phenomena, and how 
intravitreal stability of biologicals translates into potential changes in PK, toxicity and 
efficacy. 
The retinal entry and transretinal migration of biologicals depend on factors such 
as molecular weight, structure, charge and lipophilicity (El Sanharawi et al., 2010; 
Balaratnasingam et al., 2015; del Amo et al., 2017). The first barrier upon IVT 
injection of a biological is to penetrate the inner limiting membrane (ILM), the retinal 
layer at the retina’s vitreal border. The thickness of ILM varies topographically, during 
aging and in certain disease states, although the impact of these changes is yet to be 
investigated (El Sanharawi et al., 2010; del Amo et al., 2017). In studies with FITC-
dextrans of various molecular weights (Mr), the retinal exclusion limit, i.e. the maximal 
size of particles capable of retinal penetration, was determined as 76 kDa and 100 kDa 
with fixed and unfixed human retinal tissues, respectively (Jackson et al., 2003). There 
are indications of similar as well as larger Mr thresholds resisting transretinal migration 
in different layers of the retina (El Sanharawi et al., 2010; del Amo et al., 2017). 
Retinal penetration studies with multiple biologicals and macromolecules in 




al., 2010). One of the earliest studies supported Mr being a major factor as a Fab 
fragment was observed to diffuse through the whole retina, whereas the larger, full-
size mAb trastuzumab failed to penetrate even the ILM (Mordenti et al., 1999). 
Bevacizumab (a full-sized mAb; 150 kDa) was however demonstrated to penetrate the 
full thickness of the retina in rabbits (Shahar et al., 2006), mice (Kim et al., 2009), and 
cynomolgus monkeys (Heiduschka et al., 2007). Similarly, retinal penetration has also 
been demonstrated, e.g., with ranibizumab (a Fab-fragment; 48 kDa) in rabbits 
(Gaudreault et al., 2007) and rhesus monkeys (Mordenti et al., 1999), and with ziv-
aflibercept (VEGFR-2 Fc fusion protein; 115 kDa) in rabbits (Ramon et al., 2018). 
Hence, observations of molecules larger than proposed diffusion limits nonetheless 
penetrating the retina have evoked discussion of other mechanisms, including active 
transport mechanisms (Eng & Kertes, 2006; Heiduschka et al., 2007; Terasaki et al., 
2015). Since dissimilar penetration has been observed with biologicals of equal sizes, 
the possibility of the biologicals’ target specificities playing a role cannot be ruled out 
(Shahar et al., 2006; Heiduschka et al., 2007; El Sanharawi et al., 2010). Furthermore, 
as bevacizumab was shown to distribute the full thickness of the retina after a high 
IVT dose, it has also been proposed that higher doses could overwhelm the potential 
diffusion barriers and that retinal permeation might hence be related to dose (Shahar 
et al., 2006). Similar results were seen after IVT administration of high doses of 
pooled human IgGs in rabbit eyes (Han, 2004). The proposed dose-dependency on 
retinal penetration could be clinically relevant since commonly used doses of anti-
VEGF biologicals are more than enough to exhaust free vitreal VEGF (Stewart 
2018a), however, there currently seems to be little experimental evidence to support 
this. Although poorly investigated, the influence of charge has also been speculated as 
the dissimilar retinal penetration of tissue plasminogen activator and its analogue 
tenecteplase was attributed to their charge differences (Kwan et al., 2006). 
Research on the retinal penetration of biologicals has predominantly been done 
with more qualitative methods, e.g., immunohistochemistry and 
microautoradiography, while truly quantitative estimates of the retinal penetration and 
distribution of biologicals are sparse. Since these studies have commonly been done 
with animal eyes, the translation to (diseased) human eyes remains somewhat vague 
(Eng & Kertes, 2006). Furthermore, whether penetrating the full thickness of the retina 
is required for achieving clinical efficacy is not fully established, as this may differ 
depending on different biologicals’ modes and sites of action (Eng & Kertes, 2006; 
del Amo et al., 2017; Mehta et al., 2019). Although the rationale for developing 
smaller biologicals, such as the anti-VEGF agents ranibizumab and brolucizumab, is 
partially based on the assumption that a smaller size is favorable for efficient retinal 
penetration (Ferrara et al., 2007; Magdelaine-Beuzelin et al., 2010; Browning et al., 
2012), this, however, seems to be mostly hypothetical and not necessarily 
experimentally supported. There is clearly a need for comprehensive and systematic 
studies on the factors influencing retinal penetration of biologicals (Hutton-Smith et 
al., 2017) and for the development of new methodologies. 
As biologicals permeate poorly through the BAB and the BRB, their vitreal 
clearance is considered to take place primarily via the anterior route, i.e., by diffusion 
to the anterior segment and subsequent removal with the aqueous humor outflow to 
Schlemm’s canal (Shatz et al., 2016; del Amo et al., 2017; Awwad et al., 2017). This 




(Loyet et al., 2019) and is further supported by several PK modelling studies (Hutton-
Smith et al., 2016; del Amo et al., 2017; Hutton-Smith et al., 2017; Lamminsalo et 
al., 2018; Rimpelä et al., 2018). Intravitreal half-life of biologicals correlates strongly 
with the hydrodynamic size but less strongly with the molecular weight of the 
biological, as only increases in hydrodynamic size caused a linear increase in vitreal 
half-life due to resulting differences in molecular diffusivity (Gadkar et al., 2015; 
Shatz et al., 2016; Rimpelä et al., 2018; Crowell et al., 2019). 
Other clearance mechanisms and elimination routes have been proposed and 
described in the literature. While there is some support for the role of posterior 
clearance pathways (Gaudreault et al., 2005; Heiduschka et al., 2007; Krohne et al., 
2012), their contribution remains unclear and their significance is nonetheless 
currently considered low when compared to elimination via the anterior route (Gadkar 
et al., 2015; del Amo et al., 2017; Deissler et al., 2017; Mehta et al., 2019). 
The role of FcRn-mediated recycling and transcytosis on ocular drug disposition 
of biologicals has been widely speculated but remains controversial. Ocular 
expression of FcRn in humans has been observed in several locations, e.g., in the 
retina, ciliary body, the vascular components of the BRB and the RPE (van Bilsen et 
al., 2011; Krohne et al., 2012; Powner et al., 2014). Furthermore, FcRn expression 
may be upregulated in certain disease states (Kim et al., 2009; Dithmer et al. 2016). 
FcRn-mediated posterior clearance has been speculated to account for the surprisingly 
small ocular half-life difference between bevacizumab, (a full-size mAb, 150 kDa), 
and ranibizumab, (a Fab fragment 48 kDa) (Krohne et al., 2012). Fc-containing 
biologicals were demonstrated to be taken up by human RPE and primary porcine RPE 
cells in vitro whereas this uptake was inhibited with an anti-FcRn antibody (Dithmer 
et al., 2016). In the same study, transport was observed with a porcine RPE-choroid 
organ explant culture, corroborating the role of FcRn in the recycling and transcytosis 
of biologicals in the posterior eye segment (Dithmer et al., 2016). Accordingly, IVT 
administered bevacizumab penetrated the retina and was eliminated into the systemic 
circulation through the BRB in wild-type mice but not in FcRn knockout mice (Kim 
et al., 2009). Furthermore, in the same in vivo study by Kim et al (2009), posterior 
clearance of bevacizumab was more rapid in laser-photocoagulated rat retinas, 
concluded to be a result of upregulated FcRn expression. Vis-à-vis, the role of FcRn 
in mediating the ocular entry from the systemic circulation has been proposed, e.g. 
with aflibercept and bevacizumab (Magdelaine-Beuzelin et al., 2010). After IVT 
injections, small amounts of bevacizumab (Bakri et al., 2007a), but not ranibizumab 
(Bakri et al., 2007b), were detected in the serum and the fellow uninjected eye in 
rabbits. Intriguingly, after bevacizumab injection in only one eye, regression of 
neovascularization was also observed in uninjected fellow eyes of some diabetic 
retinopathy patients, with the ocular entry hypothesized to be mediated by FcRn 
(Avery et al., 2006). Although FcRn has been speculated to have a role in the ocular 
entry, distribution, and clearance of biologicals, it has also been argued to be only a 
minor or even insignificant contributor in the vitreal half-life of biologicals (Mehta et 
al., 2019), with the issue yet to be conclusively elucidated. 
Whether the FcRn-binding plays an equal role in the PK of native Fc-containing 
proteins and Fc-fusion proteins has been speculated (Dithmer et al., 2016). In vitro 
studies with retinal endothelial cells (REC), cells lining the retinal capillaries and 




of bevacizumab and aflibercept (Deissler et al., 2016; Deissler et al., 2017). A follow-
up in vitro study concluded that a fraction of uptaken aflibercept is destined for 
lysosomal degradation unlike bevacizumab, indicating a dissimilar fate between IgG 
and Fc fusion proteins (Deissler et al., 2018). An in vivo study in rabbits demonstrated 
that annulling FcRn-binding by changing the Fc-domain to a coiled-coil domain on a 
VEGF-Trap fusion protein prolonged vitreal and retina/choroid half-lives by 39% and 
130%, respectively, owing to diminished FcRn-mediated elimination (Joo et al., 
2017). These findings support the hypothesis that as the FcRn acts as an efflux 
transporter, the presence of Fc domain would be a crucial determinant in the 
disposition of intravitreal biologicals (Kim et al., 2009). On the other hand, they are 
in contrast with an in vivo study demonstrating that, regardless of its capacity for 
FcRn-binding, Fc alone had Fab-like ocular PK (Gadkar et al., 2015). Furthermore, as 
the ocular PK of a null IgG (an IgG with abolished Fc receptor binding) was similar 
to that of an intact IgG, the study concluded FcRn binding to have little clinical impact 
on ocular PK in comparison to systemic PK, possibly due to modest levels of FcRn 
expression in the eye. 
2.3.2 Diseases of the posterior eye segment 
Diseases of the posterior segment tissues are the leading cause of visual impairment 
and blindness worldwide (Awwad et al., 2017). Despite these diseases manifesting 
with somewhat similar symptoms, they affect different cell types (del Amo et al., 
2017). Although e.g. inflammation has been recognized in the aging retina (Chen et 
al., 2010) and as a central component of the underlying pathogenesis in many retinal 
diseases (Pascual-Camps et al., 2014), various other factors contribute to each disease. 
Nonetheless, as many of these diseases are age-related, their incidences are projected 
to increase in the following decades due to increased life expectancy (Delplace et al., 
2015). This poses as a source of significant pressure on healthcare systems worldwide.  
Age-related macular degeneration (AMD) is currently the most frequent cause 
of legal blindness among the elderly populace in the developed world (Kinnunen et 
al., 2012; Ghasemi et al., 2018). While peripheral vision remains unaffected, AMD 
leads to progressive loss of central vision. The etiology of this disease is still not fully 
understood, but multiple factors such as age, genetic predisposition, smoking, and 
other environmental causes contribute to the pathogenesis (Kinnunen et al., 2012; 
Volz & Pauly, 2015; Kamao et al., 2018). Early AMD is characterized by the 
formation of drusen, i.e., deposits of cellular debris between the choroid and RPE, that 
restrict nutrient supply to the RPE and overlying photoreceptors (Volz & Pauly, 2015; 
Bandello et al., 2017). Advanced AMD is clinically classified in two distinguished 
forms: the dry form and the more severe and faster progressing exudative wet form 
(10-20% of patients) (Kinnunen et al., 2012; Dolgin 2017); although distinct in 
pathophysiology, wet AMD often progresses from (early) dry AMD (Delplace et al., 
2015; Dolgin, 2017). The formation of drusen remains the main characteristic in dry 
AMD, with the associated impairment of nutrient supply eventually leading to large 
areas of photoreceptor and RPE atrophy in advanced dry AMD, also known as 
geographic atrophy (GA). The hallmark of wet AMD, and the distinguishing feature 
between the two forms, is choroidal neovascularization (CNV), i.e., the formation of 




triggered by hypoxic conditions and driven by the RPE’s overexpression and release 
of pro-angiogenic factors, most importantly VEGF (Kinnunen et al., 2012; Delplace 
et al., 2015). These new vessels extending from the choroid to the RPE and retina are 
fragile and fenestrated, resulting in RPE and even retinal detachment due to underlying 
fluid leakage and hemorrhaging, eventually leading to cell death and loss of vision 
(Peng et al., 2010; Volz & Pauly, 2015). Currently, only wet AMD can be treated with 
pharmaceuticals as several candidates for preventing RPE and photoreceptor damage 
in GA have failed in clinical trials, making the progression of dry AMD so far 
unstoppable (Bandello et al., 2017). 
The prevalence of both type I and type II diabetes is projected to increase 
dramatically in the following decades, along with diabetes-associated complications. 
Diabetic retinopathy (DR) is the most common complication and microvascular event 
of diabetes, and the most common cause of vision loss in working-age individuals 
(Duh et al., 2017; Wang & Lo, 2018); out of the nearly 300 million diabetics 
worldwide, over a third are estimated to have DR and in a third of these cases, the 
condition is sight-threatening (Gardner & Chew, 2016). Early stage DR is categorized 
to be non-proliferative (NPDR), whereas proliferative DR (PDR) is typical in the 
advanced stage. During NPDR the patients can be asymptomatic, while significant 
vision loss can be seen in PDR patients (Duh et al., 2017; Wang & Lo, 2018). Overall, 
by disturbing multiple biochemical processes, hyperglycemia damages blood vessels 
in the retina (Stewart 2017; Wang & Lo, 2018). Increased vascular permeability and 
capillary occlusion/ degeneration during NPDR manifest as characteristic pathologies, 
such as cotton wool spots, intraretinal hemorrhages, and microaneurysms (Duh et al., 
2017; Wang & Lo, 2018). Gradually worsening non-perfusion during NPDR leads to 
ischemia and subsequent hypoxia, triggering an angiogenic response, e.g., via VEGF 
upregulation. The pro-angiogenic factors stimulate neovascularization in the preretinal 
space, the defining characteristic of PDR. Like in wet AMD, the newly formed blood 
vessels are aberrant and can in severe cases burst, resulting in significant 
hemorrhaging into the vitreous, effectively clouding the patient’s vision. Moreover, 
DR patients can develop a pathologic complication called diabetic macular edema 
(DME), where due to the breakdown of BRB, leaking fluids and proteins accumulate 
sub- and intraretinally (Stewart 2017; Wang & Lo, 2018). Macular swelling due to 
this fluid build-up is a frequent occurrence and DME-associated vision impairment is 
the most common cause of vision loss in DR patients. While glycemic control is the 
firm basis for diabetes treatment and thus preventing the occurrence and progression 
of DR, anti-VEGF treatments against neovascularization (in PDR) and changes in 
vascular permeability (in DME) are also used (Gardner & Chew, 2016). 
Glaucoma affects 70-80 million people globally and is the second most common 
cause for blindness (Foldvari & Chen, 2016). Glaucoma is a term used to describe a 
collection of multifactorial neurodegenerative diseases where, regardless of 
mechanisms and pathways, the characteristic degeneration and death of retinal 
ganglion cells (RGC) leads to optic nerve damage and progressive and permanent 
vision loss. Elevated intraocular pressure (IOP) is the main associated risk factor and 
while symptomatic glaucoma management is primarily carried out with IOP-lowering 
pharmacotherapy, IOP control in some patients is challenging, while other patients 
experience RGC impairment even at normal IOP (Johnson et al., 2011; García-




translate into salvaging retinal function, direct neuroprotection has been proposed to 
prevent visual impairment, especially since the pathogenesis of glaucoma has been 
linked to deficiencies of certain neurotrophic factors (Johnson et al., 2011; Foldvari & 
Chen, 2016).  
Retinitis pigmentosa (RP) is a class of inherited retinal dystrophies featuring 
gradual degeneration and loss of photoreceptors. RP has a global prevalence of 
approximately 1:4000 and exhibits clinical and genetic heterogeneity; the genetic 
predisposition to RP is complex as the contribution of more than 100 mutations in over 
40 genes have been linked to the condition, although the genotypes of most patients 
are unknown (Hartong et al., 2006; Ferrari et al., 2011; Birch et al., 2013). In most 
cases the outer retina alone is initially affected; the outer retina has few cone 
photoreceptors compared to rod photoreceptors, with the former responsible for color 
and fine vision and the latter accounting for scotopic vision. Therefore, due to 
predominant degeneration of rods, patients typically exhibit loss of night vision, as 
well as loss of peripheral vision experienced as narrowing of the visual field, i.e., 
‘tunnel vision’. RP can advance toward the macula, where cone degeneration can 
eventually result in central vision impairment and even complete blindness. In the 
atypical cone-rod dystrophy the sequence of events is reversed as cone degeneration 
takes place first. Unfortunately, there are no established, reliable treatments for 
preventing the progress of RP or restoring vision (Sahni et al., 2011; Zheng et al., 
2015). Although the recent approval of voretigene neparvovec, a gene therapy for 
RPE65 mutation-associated RP patients is a notable milestone, the identification of 
specific mutations is a prerequisite for genetic strategies, making them inherently 
limited in applicability (Sahni et al., 2011; Ameri, 2018). The slow disease progression 
and the multitude of underlying biochemical abnormalities present considerable 
challenges, and a ‘universal‘ treatment for all RP forms and stages would need to be 
independent of the degeneration etiology (Hartong et al., 2006; Birch et al., 2013; 
Zheng et al., 2015). Such pan-RP treatment strategies have so far been proposed and 
explored albeit with varying results; using anti-apoptotic factors and neurotrophic 
factors to prevent photoreceptor cell death and providing long-term neuroprotection 
are considered broadly applicable, since photoreceptor degeneration is present in all 
cases regardless of etiology. Other approaches such as mechanism-specific gene 
therapies, general neuroprotection via gene therapy, as well as regenerative therapies 
have been and are currently being explored (Sahni et al., 2011; Lipinski et al., 2015; 
Zheng et al., 2015). 
Other chronic and acute diseases of the posterior segment – some of which also 
lead to visual impairment – include retinal vein occlusion and inflammatory and 
infectious conditions, such as posterior uveitis and cytomegalovirus retinitis 
(Thrimawithana et al., 2011; Agrahari et al., 2017; Awwad et al., 2017). Treatments 
in these conditions depend for instance on the symptoms and involved pathogens and 
include antimicrobial, antiviral, and anti-inflammatory agents administered 
intravitreally as injections and implants. 
2.4 Biologicals in posterior segment diseases – Eyeing the future 
Small molecule drugs are used to combat for instance inflammation and elevated 




posterior eye segment currently rely on biologicals as the cornerstone of their 
management. Although biologicals have longer intravitreal half-lives than small-
molecule drugs, they still require administration by IVT injections on a monthly to 
trimonthly basis. Taking into account the invasiveness of intravitreal injections, the 
current situation is far removed from ideal, and there is a clear and urgent call for 
strategies to provide true long-term clinical improvements to patients without frequent 
and invasive administration. Different pharmacologic modalities as well as varying 
approaches in drug delivery, controlled release, half-life extension, as well as 
alternative administration routes and combinatorial approaches are being actively 
explored (del Amo et al., 2017, Arranz-Romera et al., 2019). However, these efforts 
are yet to yield a truly marked improvement in efficacy or to be realized as a product 
on the market (Delplace et al., 2015; Iyer et al., 2019). The following sections review 
the available biologicals as well as some of the currently studied and developed novel 
modalities and drug delivery approaches. 
2.4.1 Anti-VEGF strategies 
Since the recognition of VEGF-mediated angiogenesis as part of the pathology in, e.g., 
wet AMD and DR, the VEGF-pathway has been exploited as a target of 
pharmacotherapy. Although there is off-label use of biologicals in certain (acute) 
ocular conditions, all currently approved biologicals for ocular indications 
administered via intravitreal injection target the VEGF-pathway (Radhakrishnan et 
al., 2017; Mandal et al., 2018) and are listed in Table 3. Also, some of the plentiful 
therapeutic proteins in development for posterior segment diseases as of writing are 
listed in the Appendix as Table S1. 
 
Table 3. Biologicals used in neovascular diseases of the retina (adapted and modified from Zhang et al., 2015; de 
Oliveira Dias et al., 2016; Radhakrishnan et al., 2017; Al-Khersan et al., 2019). 





(Avastin®) Full-size humanized mAb 
Binds all VEGF-A and 
VEGF-B isoforms 
* wet AMD 
DME  
Ranibizumab 





2nd Ig domain of VEGFR-1 and 3rd Ig 
domain of VEGFR-2 fused to human 
IgG1 Fc 
VEGF-Decoy; all VEGF-A 






2nd Ig domain of VEGFR-1 and 3rd & 4th 
Ig domains of VEGFR-2 fused to human 
IgG1 Fc 
VEGF-Decoy; all VEGF-A, 





(Macugen) PEGylated RNA aptamer Binds VEGF-A165 wet AMD 
Brolucizumab 
(Beovu®) Humanized ScFv fragment Binds all VEGF-A isoforms wet AMD 
AMD, age-related macular degeneration; DME, diabetic macular edema; Fab, fragment, antigen-binding; Fc, 
fragment, crystallizable; mAb, monoclonal antibody; PEG, polyethylene glycol; PlGF: Placental growth factor; 
ScFv, single-chain variable fragment; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. *Off-
label uses. † Approved in China; currently in phase III clinical trials in USA. 
Other biologicals targeting the VEGF-pathway have demonstrated potential as 
treatments in neovascular posterior segment diseases, and many are currently in 




binding fusion protein, is currently in phase II clinical trials for wet AMD in 
combination with ranibizumab, as well as in phase I trials for DME in combination 
with aflibercept (Mandal et al., 2018; Opthea Ltd., 2018; Opthea Ltd., 2019). Instead 
of binding and capturing free intravitreous VEGF, blocking the VEGF receptor 
(VEGFR) and hence inhibiting receptor binding is a potential and intriguing strategy. 
Tanibirumab, a full-sized mAb targeting VEGFR-2 suppressed laser-induced CNV in 
a rat model (Kim et al., 2014). Ramucirumab (Cyramza®), another anti-VEGFR-2 
mAb currently approved for treating metastatic colorectal cancer is also of interest in 
controlling neovascularization in the retina (Fleetwood et al., 2014). However, as of 
2016 no clinical programs to study this had been initiated (Falcon et al., 2016). 
Another approach – with possible applications in developing biologicals in general - 
explores the benefits of enhancing VEGF binding. To allow for less frequent 
intravitreal administration by increasing the VEGF binding potency and capacity over, 
for example, ranibizumab, a VEGF dual domain antibody (dAb) was developed 
(Walker et al., 2016). These enhancements did indeed translate into enhanced potency 
using in vitro angiogenesis models. Lastly, binding of VEGF-A to its cognate receptor 
was inhibited in vitro with Affibodies, a class of small (~6 kDa) and robust proteins, 
that were engineered to target VEGFR-2 with high affinity (Fleetwood et al., 2014). 
Whereas they are amenable for production in prokaryotic hosts as well as by chemical 
peptide synthesis, they are also exciting as anti-angiogenic candidates owing to their 
considerably small size that may allow them to be applied via alternative 
administration routes, including topically as eye drops (Fleetwood et al., 2016), 
although their retinal bioavailability can be expected to be poor given that distributing 
into the vitreous and retina in clinically significant concentrations is yet to be 
demonstrated. 
While many biologicals are yet to be evaluated in clinical studies for ocular 
indications, there are interesting new therapeutic proteins just ‘outside the field of 
vision’. Brolucizumab, an anti-VEGF-A single-chain antibody fragment demonstrated 
efficacy in treating wet AMD in two completed phase III clinical trials (Iyer et al., 
2019) and has recently gained approval as a treatment for wet AMD from the FDA 
(Markham, 2019). Abicipar pegol, a PEGylated small protein targeting VEGF-A and 
the first candidate in the emerging class of antibody mimetics termed the designed 
ankyrin repeating protein (DARPin®) has also shown marked potential (Plückthun, 
2015). Results from phase II trials raised expectation that were later met in phase III 
trials as abicipar demonstrated non-inferiority to ranibizumab with a longer 
intravitreal half-life, allowing for a less frequent dosing for treating wet AMD and 
DME; a marketing license application was filed to FDA in 2019 (Allergan/Molecular 
Partners, 2018; Callanan et al., 2018). With all this said it should, however, be noted 
that the rationale of pan-VEGF targeting has been called into question. VEGFs and 
VEGF isoforms differ in their receptor binding, subsequently triggering signaling of 
varying effects in vivo (Apte et al., 2019). Moreover, some VEGF isoforms are pro-
angiogenic whereas others are anti-angiogenic and neuroprotective, thus making 
inhibition of the latter undesirable (Amadio et al., 2016).  
Some patients fail to respond to anti-VEGF therapies while others may 
experience initial improvements but become less responsive and even resistant as 
treatment progresses (Forooghian et al., 2009; Yang et al., 2016; Cabral et al., 2017). 




pathways, the induction of other compensatory angiogenic mechanisms, as well as 
upregulation of VEGF production in macrophages (Yang et al., 2016). Although the 
clinical efficacy of anti-VEGF drugs has not been reported to be affected by 
immunogenicity, a recently described method was capable of detecting and 
confirming the presence of intravitreal anti-drug antibodies (ADAs) (Wakshull et al., 
2017; Wessels et al., 2018); neutralization of anti-VEGF biologicals in the vitreous 
could be (partially) responsible for the development of resistance. Entry of ADAs from 
the systemic circulation is also possible since posterior ocular barriers may get 
compromised in different pathologies, allowing the entry of macromolecules 
(Moshfeghi et al., 2006).  
2.4.2 Non-VEGF targeting modalities 
As of early 2020, biologicals targeting VEGF are the only effective and approved 
pharmaceuticals available for treating certain posterior eye segment diseases, and the 
vast potential of utilizing other targeting modalities is yet to bear tangible fruit. Given 
the multifactorial and complex nature of these diseases it is clear that novel biologicals 
with diverse modes of action are in high demand and that for better outcomes, 
multimodal approaches, i.e., utilizing combinatory therapies, may be required 
(Arranz-Romera et al., 2019). As our understanding of the pathogenesis of posterior 
segment diseases increases, intense research on utilizing potential new targets is 
currently underway, surely to be followed by the development of new therapies (Shatz 
et al., 2018).  
Many different approaches are being studied, and the pipeline of novel 
pharmaceuticals for various ocular indications features biologicals with different 
modalities along with numerous ‘unique-in-class’ molecules as well. While the 
pipeline does include e.g. small-molecules, gene therapies, and aptamers, protein-
based biologicals are at the forefront and are the focus of this thesis. Moreover, the 
examples presented in the following chapters are in no way comprehensive. Recent 
publications provide more thorough summaries on new anti-angiogenic therapies as 
well as on other completely new and emerging modalities and strategies to treat 
posterior segment diseases (Volz & Pauly, 2015; Bandello et al., 2017; Cabral et al., 
2017; Radhakrishnan et al., 2017; Mandal et al., 2018; Stewart 2018b; Yerramothu, 
2018). 
Targeting other angiogenic pathways 
Aside from VEGF, many other factors and pathways are involved in angiogenesis and 
neovascularization, and therapeutic strategies to block or enhance them may offer 
more efficient control/inhibition of dysregulated angiogenesis in posterior segment 
diseases (Tombran-Tink & Barnstable, 2003a; Yang et al., 2016; Chakravarthy et al., 
2017; Wang & Lo, 2018). 
Pigment epithelium-derived factor (PEDF), is a multi-functional glycoprotein, 
and as one of the most potent anti-angiogenic factors also known for its neurotrophic 
activities (Tombran-Tink & Barnstable, 2003a & 2003b). In the eye, PEDF is thought 
to counteract the actions of VEGF, with neovascularization kept in balance through 
maintaining an equilibrium between these two factors (Cabral et al., 2017). This 




disrupted equilibrium, in several posterior segment diseases (Gvritishvili et al., 2010). 
The role of PEDF in AMD pathogenesis has received support as the connection 
between PEDF gene polymorphisms and AMD occurrence in northern Chinese 
populations was demonstrated recently (Hao et al., 2018). Although the effectivity of 
ocular PEDF treatment has been confirmed, for example, in an animal model of 
neovascularization, studies to validate this in humans are direly needed to bring the 
protein into clinical use (Cabral et al., 2017). 
Endoglin is a protein overexpressed in proliferating endothelial cells and 
essential for angiogenesis (Kaplon & Reichert, 2018). Carotuximab, a chimeric 
antibody targeting endoglin, was developed as an anti-angiogenesis treatment and is 
currently in multiple clinical trials in patients with varying cancer types. Furthermore, 
an ophthalmic formulation of carotuximab is under development and currently 
undergoing phase II clinical trials in patients with wet AMD as a co-therapy with 
ranibizumab (Tracon Pharma, 2018). 
Integrins are transmembrane adhesion proteins responsible for attaching cells to 
their surrounding matrix via ligands such as fibronectin, collagen and laminin 
(Ishikawa et al., 2015; Cabral et al., 2017). In wet AMD, among other integrins, α5β1-
integrins are expressed around neovascular tissues (Volz & Pauly, 2015). By 
disrupting the interaction between fibronectin and α5β1-integrin, the chimeric antibody 
volociximab mediates a pro-apoptotic effect on the proliferating vascular endothelial 
cells, in essence acting as an angiogenesis inhibitor. Volociximab underwent phase I 
studies in combination with ranibizumab in patients with wet AMD, however, the 
study was terminated, and only limited results have been published (Ishikawa et al., 
2015; Volz & Pauly, 2015). Although phase II studies were planned, the developing 
company has shifted their focus and no further clinical trials with ocular volociximab 
are underway. 
Elevated levels of vitreal insulin-like growth factor-1 (IGF-1) and insulin-like 
growth factor-2 (IGF-2) have been observed in PDR and AMD patients, respectively 
(Agarwal et al., 2015, Cabral et al., 2017). The overexpression of intraocular IGF-1 
has been linked to BRB disruption, increased vascular permeability and both retinal 
and choroidal neovascularization, whereas IGF-2 stimulates angiogenesis, making 
their inhibition an attractive approach for treating DME and DR. A strategy of 
intravenously administered human mAb teprotumumab, an IGF-1 receptor antagonist, 
takes advantage of this pathologic situation that permits biologicals to enter from the 
circulation and hence also elicit their actions in oculo, and is currently in an open-label 
phase I study in patients with DME (Agarwal et al., 2015; Stewart 2017). 
Sphingolipids are bioactive lipids recognized as signaling molecules 
participating in a variety of both physiological and pathophysiological processes (Volz 
& Pauly, 2015). Increasing evidence points to sphingosine-1-phosphate (S1P) being 
involved in modulating the inflammation and neovascularization associated with wet 
AMD, and also affecting the production of VEGF and other angiogenic factors, in 
other words having both direct and indirect regulatory roles in retinal angiogenesis 
(Sabbadini, 2011). The utility of anti-S1P mAbs has been displayed in an in vivo CNV 
model and an ocular formulation of the humanized murine-derived anti-S1P mAb 
sonepcizumab, a.k.a. iSONEP™, was developed for treating wet AMD and possibly 
other ocular disorders. Following successful phase I safety studies (Stoller et al., 




ranibizumab in the completed phase II study either as a monotherapy or in 
combination with ranibizumab (Lpath Inc. 2015; Lpath Inc. 2016). This drug 
candidate is no longer in clinical development. 
Angiopoietins (ANG), a class of vascular growth factor proteins that among 
their other biological roles function in regulating vascular development and 
permeability (Wang & Lo, 2018). While ANG-1 stabilizes vasculature and inhibits 
CNV, ANG-2 induces fluid leakage by destabilizing the vasculature and acts 
synergistically with VEGF by rendering the endothelial cells more responsive to 
VEGF and other pro-angiogenic factors (Chakravarthy et al., 2017). ANG-2 is 
upregulated in neoangiogenic diseases, hence counteracting its function could be a 
viable therapeutic strategy in treating neovascular diseases of the retina. Nesvacumab 
is an anti-ANG-2 human mAb that, through ANG-2 inhibition, decreases vascular 
permeability (Wang & Lo, 2018). It did not provide sufficient efficacy in combination 
with aflibercept in wet AMD and DME patients, failing to proceed past phase II trials. 
Other anti-ANG biologicals are nonetheless in development. The preclinical stage 
trispecific Nanobody® BI-X is engineered to bind VEGF, ANG-2 and albumin (Fuchs 
& Igney, 2017) whereas faricimab (RG7716) is a bispecific mAb against VEGF-A 
and ANG-2 (Regula et al., 2016). Generated with CrossMAb technology, faricimab 
has been further engineered to optimize its ocular PK by abolishing binding 
interactions with FcγR and FcRn (Klein et al., 2016). In studies with cynomolgus 
monkeys with laser-induced CNV, dual inhibition of VEGF and ANG-2 with 
faricimab showed superior efficacy compared to just VEGF-A inhibition with 
ranibizumab (Regula et al., 2016). Contrary to nesvacumab, it has successfully 
completed phase II trials and two phase III programmes with DME patients are 
anticipated to commence in 2019 (Roche, 2018). On the other hand, supplementing 
anti-VEGF therapy with the small-molecule pegpleranib, an inhibitor of another 
angiogenic protein, platelet-derived growth factor (PDGF) inhibitor, or with the anti-
PDGF receptor β mAb rinucumab provided no benefit in wet AMD therapy, 
prompting researchers to re-evaluate PDGFs role in ocular angiogenesis 
(Chakravarthy et al., 2017).  
Tissue factor (TF) is a cell-surface receptor for plasma coagulation factor VII 
(fVII) and its activated form fVIIa, that trigger its functions as an activator of blood 
coagulation and in regulating both physiological and pathological angiogenesis (Wang 
et al., 2014; Wells et al., 2018). Whereas TF has not been detected in normal choroidal 
epithelium or ocular vasculature, the expression of TF is upregulated in the retinas of 
AMD patients, in which TF is considered a key contributor to the underlying 
inflammatory and angiogenic processes and to the overall progression of the disease 
(Hu, 2018; Wells et al., 2018). Hence, different TF-targeting approaches are studied 
and evaluated, and several TF-targeting mAbs are in preclinical and clinical studies 
for treatment of AMD and other pathological neovascular diseases (Hu, 2018). For 
example, an anti-TF mAb decreased TF and VEGF expression, and reduced lesion 
area in a murine model of CNV (Wang et al., 2014). An antibody-like Fc 
immunoconjugate ICON-1 has two proteolytically inactivated human fVIIa as 
targeting domains and blocks endogenous fVII by binding to TF with high affinity. 
Moreover, as the Fc domain acts as an effector, ICON-1 bound to TF on the surface 
of new vessels can also trigger the cytolytic reduction and/or removal of this 




well-tolerated in a completed phase I/II trial also demonstrating preliminary evidence 
of efficacy against CNV in wet AMD patients (Wells et al., 2018). This prompted 
progression to a phase IIa study in wet AMD patients where ICON-1 administered as 
monotherapy and in combination with ranibizumab was compared to ranibizumab 
monotherapy (Hu, 2018). At 6 months, ICON-1 showed signs of biological activity as 
patients receiving combination therapy had visual acuity gains comparable with 
ranibizumab but required fewer treatments and had longer treatment-free intervals 
(Gonzalez & Burian, 2017). Further efficacy studies are ongoing as repeated 
intravitreal ICON-1 injections both in combination with and as a maintenance therapy 
after aflibercept are evaluated in a phase IIb study in wet AMD patients with CNV 
(Iconic Therapeutics, Inc., 2018). 
Regardless of the promise and achieved success of various anti-angiogenic 
biologicals, the several unfortunate failures cannot be overlooked but ought to be 
heeded as words of warning. Retinal physiology and pathological ocular angiogenesis 
involve the interplay of several pro- and anti-angiogenic factors (Cabral et al., 2017). 
Hence, it is becoming clear that a more comprehensive understanding of their 
functions, cooperation and overall contribution in the maintenance of retinal 
vasculature and the pathogenesis of diseases must be attained before substantial 
breakthroughs, such as fully counteracting ocular pathologic angiogenesis, can be 
reached. 
Immune modulation and complement inhibition 
As the immune system is considered to play key roles in the pathology of, for example, 
AMD, targeting and modulating associated components, both innate and adaptive, are 
potentially viable as therapeutic strategies (Gehrs et al., 2006; Hollanders et al., 2015; 
Kim et al., 2015; Volz & Pauly, 2015; Bandello et al., 2017). Studies linking increased 
activation of the adaptive immune system to AMD development and progression have 
led to multiple trials evaluating the augmentation of existing anti-VEGF therapies with 
intravitreal and systemic anti-inflammatory biologicals (Volz & Pauly, 2015). 
Elevated levels of cytokines, and especially certain interleukins (IL), such as IL-
6, have been observed in DME patients and IL-6 is also associated with DR 
pathogenesis and breakdown of BRB (Agarwal et al., 2015). The feasibility of IL-6 
blockage as a DME treatment was confirmed with EBI-029, a humanized anti-IL-6 
antibody, which was shown to reduce CNV in a preclinical rat model (Schmidt et al., 
2014). Furthermore, much like with teprotumumab, the pathophysiology of DR is 
exploited with the intravenous administration of humanized anti-IL-6 receptor mAb 
tocilizumab, a treatment approach currently in phase II trials in DME patients 
(Agarwal et al., 2015; Stewart 2017). Additionally, combining systemic daclizumab, 
a humanized mAb targeting IL-2 receptor subunit α, with intravitreal anti-VEGF 
therapy decreased the number of required injections in a phase II study in AMD 
patients with CNV (Nussenblatt et al., 2010). On the other hand, augmenting 
intravitreal anti-VEGF therapy with systemic infliximab, a chimeric mAb against the 
pro-inflammatory cytokine tumor necrosis factor α (TNF-α), failed to demonstrate 
additional benefit and did not reduce the number of required IVT injections in the 
same preliminary study. Some case reports have nonetheless described patients 




and adalimumab (a humanized anti-TNF-α mAb) (Pascual-Camps et al., 2014) and 
even from systemic adalimumab (Fernández-Vega et al., 2016), raising cautious 
optimism of immunosuppressive (co-)therapy in AMD. While the roles of , e.g., TNF-
α and other cytokines are recognized in the pathogenesis of retinal neovascularization 
and macular edema, definitive evidence of beneficial effects of immune mediators in 
AMD and other macular diseases remain somewhat sparse, calling for further 
preclinical and clinical assessment (Nussenblatt et al., 2010; Pascual-Camps et al., 
2014; Volz & Pauly, 2015; Mandal et al., 2018).  
The complement system is a tightly controlled cascade of mediators that acts as 
part of the innate immune system in defense against, e.g., pathogens (Gehrs et al., 
2006). Dysregulation of the local complement system has been linked to AMD and 
especially to GA (Ferrington et al., 2016; Holz et al., 2018). Several biologicals 
targeting different factors of the complement system have been evaluated preclinically 
and in clinical trials for ocular indications (Volz & Pauly, 2015; Holz et al., 2018). 
Lampalizumab is a humanized Fab fragment that selectively inhibits complement 
factor D but failed to demonstrate efficacy in treating GA in a phase III trial with dry 
AMD patients. As other clinical trials have proven other complement inhibitors, such 
as eculizumab and tesidolumab, ineffective as monotherapies against GA, this 
warrants questions on the feasibility of complement inhibition as a therapeutic 
strategy, at least in GA treatment (Dolgin, 2017; Holz et al., 2018). Again, these 
clinical trial failures underline the need for a more comprehensive understanding of 
the pathophysiology of these complex diseases, especially when novel modalities are 
developed and evaluated. 
Neuroprotection 
The involvement of various cytokines, growth factors and neurotrophic factors has 
been implicated in posterior segment diseases and their application in patients with 
posterior segment disease has piqued researchers’ interest for decades (LaVail et al., 
1992; Birch et al., 2013). Furthermore, their ophthalmologic uses are not limited to 
just conditions with certain etiologies and they are therefore possibly more universally 
applicable (Pardue & Allen 2018). Different neuroprotective approaches range from 
utilizing exogenous proteins to targeting the receptors and signaling pathways of these 
proteins (Kimura et al., 2016).  
One of the most studied neurotrophic factors, the neuropoietic cytokine ciliary 
neurotrophic factor (CNTF), has in vitro been shown to protect rod and cone 
photoreceptors from neurodegeneration and light damage (Chong et al., 1999; Sieving 
et al., 2006; Li et al., 2010; Li et al., 2018), enhance axonal regeneration and RGC 
survival (Van Adel et al., 2005; Leaver et al., 2006; Cen et al., 2007; Müller et al., 
2009), and increase RPE survival (Li et al., 2011). Several in vivo studies with CNTF 
and Axokine (an engineered recombinant human CNTF analogue; Panayotatos et al., 
1993) have rather consistently demonstrated CNTF-mediated rescue of photoreceptors 
and/or improvement of their function in different animal models of retinal disease, 
such as glaucoma and optic nerve injury (Ji et al., 2004; Leaver et al., 2006; Pease et 
al., 2009; Kimura et al., 2016), diabetic retinopathy (Ma et al., 2018), CNGB3-




al., 2010; Rhee et al., 2013; Lipinski et al., 2015), and pathological neovascularization 
(Bucher et al., 2016). CNTF’s translation to the clinic has, however, been arduous.  
In preclinical studies, CNTF has been delivered directly via IVT injection in 
most models, but this approach has been deemed infeasible for long-term treatment 
due to several limitations (Wen et al., 2012). Like most neurotrophic factors, CNTF 
is an unstable protein (Hottinger & Aebischer, 1999; Fandl et al., 2006), and has a 
short vitreal half-life with diffusion and protein degradation possibly accounting for 
the rapid clearance (Leon et al., 2000; Beltran et al., 2007). Therefore, as the effects 
of IVT administered CNTF are transient, frequent invasive IVT injections would be 
required for achieving sustained neuroprotection, a significant impediment as many 
posterior segment diseases can progress slowly over years and decades and making 
this approach impractical for long-term neuroprotection (Tao et al., 2002; Ghasemi et 
al., 2018). Moreover, the fact that exogenous CNTF can paradoxically suppress retinal 
function and impair vision in a dose-dependent manner (Wen et al., 2006; Beltran et 
al., 2007; McGill et al., 2007) also prevents administering CNTF as large IVT bolus. 
This effect has been observed e.g. as suppressed electroretinogram responses and 
attributed to CNTF-induced biochemical and morphological changes in the 
phototransduction machinery of rod photoreceptors and was shown to be fully 
reversible (Wen et al., 2006). Nevertheless, efficient means for avoiding associated 
adverse effects of repeated bolus injections are not available. Therefore, clinical trials 
with IVT administered CNTF injectables were not initiated (Tao et al., 2002; Sieving 
et al., 2006). 
Various measures have been taken to overcome these limitations, most often by 
providing sustained CNTF release into the vitreous. NT-501 (a.k.a. Renexus®), an 
intraocular implant with immortalized CNTF expressing cells encapsulated inside a 
semi-permeable capsule, has been studied in several clinical studies in GA and RP 
(Ghasemi et al., 2018). Despite successful proof-of-concept studies (Zhang et al., 
2011), Renexus® therapy eventually failed in GA and RP patients due to 
disappointing efficacy and clinical outcomes (Kauper et al., 2012; Birch et al., 2013; 
Birch et al., 2016). Different reasons for these failures, including poor understanding 
of disease pathology and hence choice of therapeutic, have been discussed (Wong et 
al., 2017). However, other indications for Renexus® are still actively explored. 
Following observations in earlier phase I trials, Renexus® is currently in phase II trials 
in glaucoma patients (Ghasemi et al., 2018), and after encouraging efficacy results in 
a completed phase II trial in patients with macular telangiectasia type 2 (Chew et al., 
2019), patient recruitment for two parallel phase III trials with Renexus® is currently 
ongoing. These clinical trials are far from completion and comprehensive results 
pertaining efficacy are still a few years down the road. Based on dose-response studies, 
CNTF-mediated impairment of retinal function is unlikely to be of concern with 
therapeutic CNTF doses (McGill et al., 2007) and therefore neither with the Renexus® 
approach. Some caution is nevertheless warranted and human patients receiving such 
CNTF-based treatment should be monitored closely until the clinical relevance and 
possible impact of CNTF-mediated negative regulation is conclusively resolved. 
Nevertheless, as the feasibility of the concept has been demonstrated – not only with 
CNTF, but also with soluble VEGFR-1 (Kontturi et al., 2015) and a complement 




altogether attractive approach to circumvent frequent IVT injections of biologicals in 
treating (vitreo-)retinal and choroidal diseases (Wong et al., 2017).  
IVT administered nerve growth factor (NGF) protects retinal cells from damage 
in an induced retinal detachment model in rats (El Sanharawi et al., 2010). There are, 
however, conflicting reports of NGF’s effects on RGC survival and regeneration. 
Interestingly, reduced progressive RGC loss and improved visual outcomes in 
hypertensive eyes of rats were observed upon topical NGF administration (Lambiase 
et al., 2009). Although the same study evaluated the safety of topical NGF in a first-
in-human trial with 3 glaucoma patients, and a different pilot study in RP patients 
reported of a subjective feeling of improved vision in 3 out of 8 patients receiving 
NGF eye drops (Falsini et al., 2016) further studies are required to demonstrate the 
efficacy of NGF treatment, for example, in patients with retinal neurodegenerations 
(Kimura et al., 2016). 
The brain-derived neurotrophic factor (BDNF) is a potent neuroprotective agent. 
In the eye it is critical to RGCs in retinal development and in response to optic nerve 
injury, as well as in visual system function (Kimura et al., 2016; Mysona et al., 2017). 
Reduced lachrymal and optic disc BDNF levels have consistently been observed in 
glaucoma patients, making BDNF a potential glaucoma biomarker. Exogenous BDNF 
protects RGCs from damage, and the induction of BDNF overexpression by virally 
mediated gene therapy and other agents also promotes RGC survival (Ko et al., 2001; 
Mysona et al., 2017), whereas it can also slow down photoreceptor degeneration in 
mice (LaVail et al., 1998). As with NGF, topical BDNF eye drops are effective in 
rescuing visual function in mice, although both strategies remain to be validated in 
humans (Domenici et al., 2014; Mysona et al., 2017). Even so, BDNFs effects on 
neuroprotection and in delaying RGC are short-lived and even repeated IVT injections 
cannot guarantee RGC survival, making its therapeutic value in posterior segment 
diseases limited especially when used alone (Klöckler et al., 1998; Ko et al., 2001; 
Harada et al., 2015). Furthermore, regardless of the positive effects, the ocular 
application of BDNF has been shown to upregulate nitric oxide synthase, which in 
turn is harmful to RGCs (Klöckler et al., 1998; Zhang et al., 2005).  
Glial cell-line-derived neurotrophic factor (GDNF) exerts neuroprotection on 
retinal cells in different retinal pathologies, and for example RGC rescue as well as 
retardation of photoreceptor degeneration have been demonstrated along with 
functional rescue (Hauck et al., 2006). This neuroprotection takes place even at low 
GDNF concentrations provided that its delivery is maintained long-term (García-
Caballero et al., 2017). Interestingly, GDNF is observed to exert its neurotrophic 
effects on photoreceptors both in a direct and an indirect manner; in mouse and porcine 
retinas, receptors for GDNF have been found mostly in retinal Müller glial cells 
instead of photoreceptors themselves (Delyfer et al., 2005; Hauck et al., 2006). These 
cells in turn mediate the upregulation and release of other factors shown to support 
photoreceptors directly, a mechanism proposed also for other neurotrophic factors 
(Hauck et al., 2006; Harada et al., 2015; Kimura et al., 2016). All things considered, 
GDNF has been shown to increase RGC survival in preclinical animal models of 
glaucoma and as such it displays therapeutic potential in the treatment of glaucoma 
and RP. 
Mesenchephalic astrocyte-derived neurotrophic factor (MANF) was recently 




increases successful regeneration (Neves et al., 2016). RGCs were subsequently 
shown to express MANF and to respond to exogenous MANF treatment in in vitro 
and in vivo models of glaucoma and RP, concluding MANF to be a potential 
therapeutic candidate for promoting RGC survival (Gao et al., 2017; Lu et al., 2018). 
Whereas several neurotrophic factors have untapped therapeutic potential in 
neurodegenerative diseases of the CNS and posterior eye segment, their 
pharmaceutical development is by-and-large still in the earlier stages with CNTF and 
NGF as the only one to have been tested in the eye in clinical trials (Kimura et al., 
2016; Pardue & Allen 2018). Furthermore, as their effects are tightly linked to dosage 
and as high IVT doses may in fact be harmful to retinal function, the continuous 
delivery of small doses is likely safer and more effective (El Sanharawi et al., 2010). 
Combating oxidative stress and toxic byproduct buildup 
The presence of misfolded and aggregated proteins is associated with AMD. It has 
been suggested that this arises partly due to age-related chronic oxidative stress and 
overwhelmed clearance capacity (Kivinen et al., 2014; Kaarniranta et al., 2017). 
Hence, the prevention and removal of protein aggregates has been proposed as a means 
of controlling and/or hindering the progress of this disease (Kivinen et al., 2014; 
Ferrington et al., 2016). Heat shock proteins (Hsps) function as molecular chaperones, 
i.e., in maintaining and restoring correct 3D structures of nascent and misfolded 
proteins, and in preventing the formation and accumulation of potentially cytotoxic 
protein aggregates in cells (Yu et al., 2001). Should this fail, proteins are targeted for 
proteasomal disposal (Kivinen et al., 2014). Furthermore, Hsps inhibit apoptosis, a 
mechanism of programmed cell death that occurs also in many posterior segment 
diseases (O’Reilly et al., 2010). Consequently, elevated retinal levels of Hsps – 
induced, e.g., in response to oxidative stress – have been observed in AMD patients 
(Decanini et al., 2007; Urbak & Vorum 2010; Ferrington et al., 2016). Interestingly, 
it also seems that such a capability of mounting a response to stress declines in aging 
cells, such as in the RPE of AMD patients (Kivinen et al., 2014; Subrizi et al., 2015). 
Therefore, strategies utilizing the cytoprotective activities of Hsps in neuroprotection 
of the retina has generated interest (O’Reilly et al., 2010). 
The widely studied Hsp27 and Hsp70 proteins are strongly induced by stress, 
and as they play important roles in protecting the retina, they are attractive as potential 
therapeutics in retinal diseases (Urbak & Vorum 2010; Chidlow et al., 2014). Hsp27 
has shown protective effects on neuronal cells against apoptosis and is a therapeutic 
candidate, for example, for protecting RGCs in glaucoma (Kalesnykas et al., 2007; 
O’Reilly et al., 2010). Potential of Hsp70 in photoreceptor survival after retinal 
detachment –  a condition associated with various retinal diseases – was noted as 
Hsp70 was up-regulated in an in vivo animal disease model and prevented the 
activation of cell death pathways, whereas administration of a Hsp70 inducer was also 
demonstrated to result in decreased photoreceptor apoptosis (Kayama et al., 2011). In 
vitro, Hsp70 was shown to bind to perinuclear protein aggregates under proteasome 
inhibition in ARPE-19 cells; owing to decreased lysosomal enzyme activity the 
proteasomal degradation diminishes during aging in the RPE, resulting in lipofuscin 
and protein aggregate formation and accumulation (Kivinen et al., 2014). Hsp70 has 




involve the maintenance of the lysosomal enzymes’ activity in the removal of harmful 
protein species. Furthermore, after uptake into ARPE-19 cells, exogenous rhHsp70 
localized in late endosomes and lysosomes and protected the cells from oxidative 
stress, while diffusion of IVT rhHsp70 from vitreous to the RPE was observed in a 
porcine ex vivo model, providing a proof-of-concept of targeting lysosomal protein 
aggregates with a Hsp70 chaperone as a potential AMD therapy (Subrizi et al., 2015). 
The neuroprotective therapeutic utility of Hsp70, especially in acute retinal traumas, 
is also appealing as IVT administered Hsp70 reduced photoreceptor cell apoptosis 
after light damage in rat eyes in vivo (Yu et al., 2001). Despite numerous studies 
providing proof of the utility of Hsp therapy in posterior segment diseases, sustained 
delivery approaches for long-term neuroprotection with Hsps seem to be lacking, and 
there are notable gaps in our understanding of the roles of Hsps in the eye and 
pathology of ocular diseases (Urbak & Vorum 2010; Chidlow et al., 2014). Hence, 
regardless of their considerable promises, treating ocular diseases with Hsp 
therapeutics is still far from realisation in the clinic. 
Amyloid beta (Aβ) is a family of highly toxic, aggregation-prone peptides most 
often associated with neurodegenerative disorders, e.g., Alzheimer’s and Parkinson’s 
(Ratnayaka et al., 2015). The presence of elevated levels of Aβs in the ageing retina, 
and especially in the extracellular debris deposits known as drusen, has been linked to 
AMD pathogenesis and progression, and was shown to lead to downregulation of 
PEDF and upregulation of VEGF expression in in vitro human RPE cultures (Yoshida 
et al., 2005; Ratnayaka et al., 2015; Radhakrishnan et al., 2017). Two Aβ-targeting 
antibodies have been developed to attenuate such effects via preventing the 
accumulation of Aβs and thus reducing the pool of these toxic compounds; an 
intravenously administered mAb and a different intravitreally administered mAb have 
both undergone phase II studies in patients with dry AMD (Singer 2014; 
Radhakrishnan et al., 2017). 
2.4.3 Drug delivery strategies for biologicals 
Although novel biologicals are being developed for ocular indications, the innate 
obstacles of their use in ocular pharmacotherapy remain (Mandal et al., 2018). As a 
result, routine administration still takes place by IVT injections in the clinic 
(Radhakrishnan et al., 2017). To improve the efficacy and ocular PK of both approved 
and emerging biologicals, numerous research efforts exploring different drug delivery 
approaches are ongoing (El Sanharawi et al., 2010; Agrahari et al., 2017; 
Radhakrishnan et al., 2017; Lau et al., 2018).  
To mitigate the safety risks and treatment burden associated with frequent IVT 
injections, one of the main development goals is to achieve less frequent and less 
invasive dosing, i.e., to make treatment more amenable to patients and clinicians alike. 
As with delivery of biologicals in general, strategies to improve ocular delivery also 
range widely (Mitragotri et al., 2014; Patel et al., 2014). From therapeutic protein 
engineering approaches to implantable systems and nanocarrier-based drug delivery 
systems, the approaches are far too numerous to be included here, and have been 
comprehensively reviewed elsewhere (Shah et al., 2010; Thrimawithana et al., 2011; 
Patel et al., 2013; Radhakrishnan et al., 2017; Lau et al., 2018). Instead, chosen 




and established approaches and strategies are briefly discussed, and the reader is 
kindly directed to a recent paper by Mandal et al., (2018) for a more in-depth review. 
Although different physical forces/phenomena, such as electrical fields and 
sonophoresis, and their application to transiently disrupt biological barriers and 
enhance the ocular penetration of biologicals are actively studied (Huang et al., 2018), 
for brevity, they are not further discussed here. 
Therapeutic protein engineering approaches 
As discussed in sections 2.2.2 and 2.3.1, retaining therapeutic protein stability is of 
paramount importance in ensuring treatment efficacy and safety. Although models to 
evaluate therapeutic protein stability in the vitreous have been developed (Patel et al., 
2015; Patel et al., 2017), they cannot fully represent the in vivo situation whereas 
studying stability in a patient-setting is impractical and unethical. Among other 
challenges, sustained ocular delivery strategies may necessitate very high protein 
concentrations whereas the protein itself needs to be resistant to different stresses and 
extended exposure to varying conditions (Tesar et al., 2017). By utilizing protein 
engineering to modify the protein, a Fab fragment for formulation in high protein 
concentrations and for enhanced stability in vitreal conditions was developed with the 
aim of enabling less-frequent dosing (Tesar et al., 2017). Whereas improved stability 
under both formulation and physiological were achieved with this approach, follow-
up studies in humans are needed to corroborate these findings. 
Many ocular drug delivery strategies are based on exploiting the eye’s 
physiology. The fusion of anti-VEGF mAbs together with a hyaluronic acid (HA) 
binding peptide increased the intraocular half-lives 3–4 fold compared to unmodified 
proteins in vivo (Ghosh et al., 2017). As a major macromolecular component of the 
vitreous, HA in this case acts as an intraocular reservoir for bound protein, slowing 
the clearance of the mAb and thus extending their therapeutic efficacy. Likewise, the 
binding of a Nanobody® to intravitreal albumin was shown to result in a 3-fold 
increase in its vitreal half-life (Fuchs & Igney, 2017), although this was most likely 
due to an increase in hydrodynamic size that results in decreased anterior clearance 
(Mehta et al., 2019). While this strategy might allow for prolonged dosing intervals, 
intravitreally administered albumin-binding biologicals may have their drawbacks. In 
addition to the limited binding capacity of vitreal albumin, the half-life extension 
imparted by albumin-binding may not be sufficient, as albumin itself has an 
intravitreal half-life of only a few days, whereas after ocular clearance the systemic 
half-life of albumin-binding biologicals may be unacceptably long (Ghosh et al., 2017; 
Mehta et al., 2019). 
Aside from specific binding to vitreal components, increasing residence time by 
modulating molecular size and/or hydrodynamic radius seems to be a viable strategy 
as increasing evidence points it to be a critical factor in intravitreal clearance of 
biologicals (del Amo & Urtti, 2015; Shatz et al., 2016; Hutton-Smith et al., 2017; 
Shatz et al., 2019). For example, the hydrodynamic radii of abicipar and pegaptanib 
are increased through PEGylation, which prolongs their residence times (Shatz et al., 
2018). PASylation®, i.e., conjugating/fusing polypeptides composed of Pro, Ala 
and/or Ser, is a technique complementary to PEGylation that has been utilized to 




Other approaches include utilizing covalent grafting of multiple Fab fragments and 
VEGF decoy receptors to HA (Altiok et al., 2016; Famili et al., 2019), and branched 
PEG (Shatz et al., 2019) to prolong the vitreal residence time. 
FcRn binding is routinely exploited with Fc-fusion proteins, such as aflibercept 
and etanercept, and is also possible with albumin-fusion proteins (Sockolosky & 
Szoka, 2015). Further modulation of this interaction to influence the PK of therapeutic 
proteins is also possible. For example, whereas bevacizumab is recycled and salvaged 
by FcRn, the Fc-fusion protein aflibercept was present in FcRn-mediated recycling-
associated organelles but also observed to be destined for lysosomal degradation in a 
bovine in vitro model (Deissler et al., 2018). Hence, further engineering of aflibercept 
could be of utility to influence this interaction and direct the protein more efficiently 
to be recycled and salvaged. On the other hand, as FcRn-mediated transport over the 
BRB contributes to the ocular elimination of bevacizumab (Kim et al., 2009), avoiding 
the FcRn binding of biologicals could instead be preferable in ocular use (Shah, 2015). 
One can argue that this would in turn also abolish FcRn-mediated recycling of 
endocytosed proteins, possibly resulting in overall shortened vitreal half-life. There is 
also evidence pointing to the contrary (Gadkar et al., 2015) although it should be noted 
that the overall relevance of posterior clearance mechanisms is – albeit under debate 
as quantitative data elucidating this is lacking – considered small (5–15%) compared 
to anterior clearance (del Amo et al., 2017; Deissler et al., 2017; Shatz et al., 2018; 
Mehta et al., 2019; Ramsay et al., 2019). Nonetheless, different factors influence the 
FcRn-binding of biologicals and serve as clues for protein engineering approaches 
(Oganesyan et al., 2014). Accordingly, multiple different strategies to modulate this 
interaction exist, and although they have mostly been utilized to impact systemic PK 
(Roopenian & Akilesh, 2007; Sockolosky & Szoka, 2015), such modulation could also 
be explored in ophthalmologic biologicals. For example, to influence the pH-
dependent binding, the affinity of the interaction can be altered via engineering the Fc 
domain by, e.g., mutating amino acids responsible for the interaction (Borrok et al., 
2015; Sockolosky & Szoka, 2015). Moreover, as regions distal to the Fc domain have 
been observed to interact with FcRn-binding (Schoch et al., 2015; Piche-Nicholas et 
al., 2018), engineering these parts could also be carried out to tune the ocular PK of 
biologicals. All in all, the significance of FcRn-binding in the ocular PK of biologicals 
is still not fully established. The overall relevance of all posterior clearance is 
considered small, and strategies to modulate the FcRn interaction may therefore have 
minimal impact on the intravitreal half-lives of biologicals, although this cannot yet 
be comprehensively stated.  
Drug delivery systems and implants 
To address and mitigate the challenges of frequent IVT injections, sustained and 
controlled release formulations, such as liposomes, hydrogels, micro- and 
nanoparticles, and different polymer matrix systems have been developed for 
biologicals (Agrahari et al., 2017; Joseph & Venkatraman, 2017; Iyer et al., 2019). 
Furthermore, there is also great interest in the development of stimuli-responsive drug 
delivery systems, capable of releasing biologicals upon external stimulus, such as light 




A recent study utilizing an ex vivo set-up to mimic sub-conjunctival 
administration and trans-scleral transport demonstrated controlled release of 
liposome-encapsulated ranibizumab (Joseph et al., 2017); the study, however, only 
quantitated trans-scleral transport whereas ranibizumab’s activity after said transport 
was not determined. Likewise, GDNF co-encapsulated with vitamin E was released 
from biodegradable poly-lactic-co-glycolic acid (PLGA) microspheres after a single 
IVT injection to the rabbit vitreous for up to 6 months in a controlled fashion resulting 
in concentrations that were earlier demonstrated to protect RGCs in an animal 
glaucoma model (García-Caballero et al., 2017). Similarly, sustained release of 
aflibercept from polymeric PLGA nanoparticles over 7 days has been described in 
vitro, although retention of aflibercept’s therapeutic efficacy in such a system remains 
to be demonstrated in vivo (Kelly et al., 2018). Many of these developments have, 
however, not been without considerable hurdles. Although the dual dAb protein 
retained activity for over 12 months and showed protection over 6 months in a primate 
model of wet AMD upon sustained release from microparticles, particle migration and 
adverse effects were also described (Adamson et al., 2016). Whereas each approach 
has advantages and challenges, common obstacles pertaining to (nano)carriers include 
the issues of reproducibility, scalability, complex fabrication and long-term stability 
in biological fluids. These problems must be solved prior to successful clinical 
translation (Agrahari et al., 2017; Joseph & Venkatraman, 2017).  
Implantable devices are another approach for sustained drug delivery and 
prolonged dosing intervals (Shah et al., 2010; Shatz et al., 2018). The Port Delivery 
System is a surgically implanted, non-biodegradable and refillable drug reservoir on 
the sclera that allows for the continuous release of therapeutic concentrations of 
biologicals into the vitreous over extended periods (Lau et al., 2018). It has been 
developed to reduce the need for repeated injections and as a less invasive 
administration method it reduces the burden of injections. The Port Delivery System 
was evaluated in a recent phase II clinical trial for the extended delivery of 
ranibizumab in wet AMD patients and is currently recruiting for pivotal phase III 
studies (Campochiaro et al., 2019). Similarly, the cell-based implant system 
Renexus® discussed in section ‘Neuroprotection’ on page 38 is an implantable 
bioreactor for the sustained in oculo production of CNTF over extended time periods, 
and ECT systems have been developed for the sustained intravitreal release of other 
ophthalmologically relevant biologicals (Kontturi et al., 2015; Annamalai et al., 
2018). Lastly, different extraocular reservoir systems have been designed for 
convenient refilling and sustained release (Joseph & Venkatraman, 2017; Lau et al., 
2018). The MicroPump System – a technology akin to insulin pumps – is a pump 
system that delivers biologicals in a controlled fashion and has been evaluated in a 
small trial for controlled release of ranibizumab. Even though the system was well 
tolerated, there were significant challenges with the implementation of this system and 
suboptimal drug effects in the study. It is unclear whether the developers will proceed 
further with the system (Lau et al., 2018; Shatz et al., 2018). 
Although various drug delivery systems have been developed to provide 
sustained and less invasive solutions for the ocular delivery of biologicals, translation 
to clinical applications has been challenging. For example, material safety and 
toxicity, carrier properties, loading capacities, maintaining therapeutic protein 




of the many roadblocks that have hampered scientists from reaching this goal. Even 
with active research and rapid progress in the field, no system has advanced to the 
clinics (Shah et al., 2010; Delplace et al., 2015; Agrahari et al., 2017; Radhakrishan 
et al., 2017). Hence, research on retinal disease pathologies, their models, as well as 
determinants of ocular barriers and PK of biologicals is still needed. Accordingly, 
close collaboration across scientific areas and fields is needed to bring innovative 
ocular drug delivery systems into the clinic to rescue and even restore vision in 
patients. 
2.5 Other approaches 
As the underlying pathogenesis of retinal diseases are diverse, in addition to the 
biologicals discussed in previous sections, various other treatment strategies have been 
explored. For example, in response to inflammation implicated in the pathogenesis of 
many posterior segment diseases (Pascual-Camps et al., 2014), several anti-
inflammatory strategies have been explored and developed, including the intraocular 
implants Iluvien® and Ozurdex® for the sustained intravitreal release of fluocinolone 
acetate and dexamethasone for treating DME (Wang & Lo, 2018). Moreover, small 
molecules inhibiting the downstream signaling of VEGFRs have been explored as 
strategies against pathological neovascularization (Delplace et al., 2015; Volz & Pauly 
2015). Apart from small molecule drugs, biologicals, and drug delivery strategies and 
systems to enhance and prolong their ocular delivery, other forms of therapy for retinal 
diseases are also under development. For brevity, only gene therapy and cell-based 
therapies are briefly discussed hereafter, and the reader is kindly pointed towards 
recent reviews on the subjects for more thorough summaries (Agrahari et al., 2017; 
Aguirre, 2017). 
Genetic predispositions contribute to many posterior segment pathologies 
(Aguirre, 2017). Gene therapy offers considerable hope in combating certain 
hereditary posterior segment diseases and is also of interest for achieving prolonged 
release of therapeutic proteins in general (El Sanharawi et al., 2010; Agarwal et al., 
2015). In other words, gene therapy may not only be utilized to replace a mutated gene 
or to supply a missing protein, but also to replace repeated injections. Furthermore, as 
an individual patient’s genetic makeup may influence the choice of therapy, treating 
AMD, for example, may become more personalized in the future (Yang et al., 2016). 
Thus far, retinal gene delivery with intravitreally injected non-viral and viral vectors 
have been studied in preclinical and clinical trials (Aguirre, 2017; Awwad et al., 
2017). Adenovirus and the adeno-associated virus have most often been utilized in the 
delivery of, for example, CNTF and PEDF gene therapies (Ishikawa et al., 2015; 
Lipinski et al., 2015; Ghasemi et al., 2018). To give a more detailed example, an 
adenovirus vector carrying a gene for sFLT-1 (soluble VEGFR-1) has been developed 
to induce the cells of the outer retina to express and secrete soluble anti-VEGF receptor 
that in turn binds VEGF, inhibiting it from binding to its receptors in the retina 
(Stewart, 2018b). Although proof-of-concept was acquired with this treatment in wet 
AMD patients, development was halted due to lower than expected performance. 
Whereas the potential in treating retinal pathologies is considerable, direct cellular 
delivery and intracellular release of the therapeutic gene are but some of the many 




hurdles and setbacks, the first ever retinal gene therapy was approved by FDA in 2018 
(Ameri, 2018). As gene editing has advanced considerably with new tools, such as 
CRISPR/Cas9 becoming available, other gene therapy approaches for retinal 
pathologies can be envisioned to follow suit. 
The possibilities of regenerative therapies, such as utilizing cell transplants in 
replacing degenerated photoreceptors and RPE are considerable as such transplants 
could potentially not only preserve vision but even restore lost vision (Delplace et al., 
2015; Zarbin, 2016). Aside from direct replacement, cells engineered to excrete, for 
example, CNTF and GDNF could also be transplanted to achieve long-term in situ 
release of these therapeutic, neuroprotective proteins (Awwad et al., 2017; Oswald & 
Baranov, 2018). Several early stage clinical trials are currently ongoing – for example 
in GA patients – to evaluate the safety and efficacy of cell therapies derived from both 
human embryonic stem cell cells and induced pluripotent stem cells (Zarbin, 2016; 
Oswald & Baranov, 2018). Regardless of notable fundamental obstacles that have 
been addressed, significant challenges such as cell manufacture, delivery and survival 
remain to be overcome before cell-based therapies can be implemented as routine 
clinical treatment alternatives in retinal pathologies. 
 
In conclusion, regardless of notable advances in the treatment of posterior eye 
segment diseases during the last 20 years, many of the obstacles remain to be tackled. 
Whereas management of diseases such as wet AMD and DR has progressed with the 
introduction of several biological anti-VEGF therapies, some patients are resistant to 
these treatments that, regardless of all efforts, still require frequent injections to 
achieve clinical benefits. Many aspects of ocular PK of biologicals remain poorly 
understood and their significance has not been fully addressed. Even with emerging 
therapeutic modalities and drug delivery approaches, we are still learning, and it may 
become apparent that multiple pharmaceuticals and even multiple drug delivery 
systems are required for the successful treatment of certain conditions. Moreover, even 
though (therapeutic) protein production methods and tools have evolved and matured 
over the last decades, obtaining adequate protein yields still requires considerable 
effort and is at times a trial-and-error process. Likewise, new methods in therapeutic 
protein screening and development are in high demand to address and tackle the 






3 Aims of the study 
This thesis deals with the production and development of biologicals and their 
therapeutic applications in treating diseases of the posterior eye segment. The main 
focus of the investigations was on the ophthalmologically relevant protein, ciliary 
neurotrophic factor (CNTF). 
 
The specific aims of this thesis were: 
 
1. To screen for optimal conditions for the expression of soluble rhCNTF in E. 
coli (I) 
2. To scale-up rhCNTF production and verify the functionality of rhCNTF (I) 
3. To further characterize the purified rhCNTF (II) 
4. To screen for appropriate storage formulations for purified rhCNTF and study 
the protein’s long-term stability in those formulations (II) 
5. To study the retinal permeation of rhCNTF (II) 
6. To provide proof-of-concept for a novel production platform for streamlined 
pharmaceutical protein development (III) 






4 Materials and Methods 
The methods and equipment employed in the studies are summarized in Table 4. 
Whereas well established and routinely used methods are not discussed here, key 
methods are discussed in more detail in the following sections. All materials and 
methods used in this thesis are described in full detail in the respective publications. 
Table 4. Overview of materials and methods used in the thesis work. 




Generation of DNA 
fragments and 
assembly of plasmid 
vectors 
Codon optimization for 
expression in E. coli 
OptimumGene™ 
(Genscript, USA) I 
Linearization of plasmid 
vectors 
Restriction enzyme 
digestion, inverse PCR I, III 
Amplification of gene 
inserts PCR, gradient PCR I, III 
Purification of DNA 
fragments and plasmid 
DNA 
Gel and PCR clean-up, 
Mini-prep, Midi-prep I, III 
Assembly of expression 
plasmids 
Gibson AssemblyTM, 
NEBuilder® I, III 
Validation of target gene 
insertion 
Colony PCR, gene 





Screening of factors for 
optimal expression 
conditions in small scale 




Estimation of soluble 




Affinity purification Batch IMAC with Ni
2+-
resin,  SDS-PAGE I, II 
Removal of high molecular 




Protein identity, molecular 
weight, fragmentation, 
purity 
SDS-PAGE, WB I, III 
rhCNTF activity & 
function 
Binding with cognate 
receptor subunit  
rhCNTF biotin labeling, 
rhCNTF – rhCNTFRα-





BrdU incorporation, ELISA II 
rhCNTF folding and 
structure 
Investigating secondary 




Thermal unfolding of 
rhCNTF; observing Th 
changes during storage 
CD, ThermoFluor II 
rhCNTF 
hydrodynamic size 
Observing rh changes 
during storage DLS II 
rhCNTF 
aggregation 
Detection of high molecular 







Table 4 continued. 




Distribution of rhCNTF in 
bovine and rat ex vivo retinal 
explants 
Preparation of retinal 
explants, fluorescent 







Distribution of rhCNTF and 
microglia in rat ex vivo retinal 
explants 
Preparation of retinal 
explants, fluorescent 










NpuDnaECΔ16 in Tobacco BY-2 




Photocleavage efficiency and 
rate of NpuDnaEC16 peptides UV365nm exposure, HPLC III 
Streamlined 
purification of 
protein of interest 
Capture of PTS-generated de 
novo rhCNTF-His6; light-
induced release of rhCNTF 
Ni2+-capture of rhCNTF-
His6 generated via PTS, 
UV365nm release of rhCNTF, 
WB 
III 
Split intein-mediated capture of 
rhCNTF- NpuDnaECΔ16 by Ni-
NTA immobilized NpuDnaEC16 
peptide; light-induced release 
of rhCNTF 
Split intein-mediated 
capture and UV365nm release 







Split intein-mediated transfer of 
biotin from capture peptide to 
rhCNTF 
Streptavidin-shift assay, WB III 
BrdU, 5-bromo-2'-deoxyuridine; CD, Circular dichroism spectroscopy; CFPS, cell-free protein synthesis; CNTF, 
ciliary neurotrophic factor; CNTFRα, CNTF α-receptor; DLS, dynamic light scattering; ELISA, enzyme-linked 
immunosorbent assay; HPLC, High-performance liquid chromatography; Iba-1, ionized calcium-binding adapter 
molecule 1, a microglial marker; IMAC, immobilized metal-ion affinity chromatography; Ni-NTA, nickel 
nitrilotriacetic acid; NpuDnaE, Nostoc punctiforme DnaE split intein; PCR, polymerase chain reaction; PK, 
pharmacokinetics; PTS, protein trans splicing; rh, hydrodynamic radius; SDS-PAGE, sodium dodecyl sulphate–
polyacrylamide gel electrophoresis; SEC, size-exclusion chromatography; Th, temperature of hydrophobic 
exposure; WB, Western blot 
4.1 Binding assay with rhCNTFRα (publication I) 
To indirectly assess the function of produced rhCNTF, an enzyme-linked 
immunosorbent assay (ELISA) assessing binding with the cognate α receptor was 
carried out. First, purified rhCNTF was reacted with 20:1 molar excess of N-
hydroxysuccinimide (NHS)-PEG4-biotin in a carbonate buffer solution in 
dimethylformamide, conjugating the biotin to exposed amines e.g. in the N-terminus 
and lysine side chains. After reaction, excess NHS-PEG4-biotin was removed and the 
biotinylated rhCNTF (bCNTF) buffer exchanged to a phosphate buffer. 
After coating the wells of a high protein-binding 96-well plate with rhCNTFRα, 
the wells were blocked with bovine serum albumin (BSA) to reduce non-specific 
binding to the plate surface. bCNTF was added to the wells and incubated to allow for 
binding to the rhCNTFRα, followed by washing the wells repeatedly to remove 
unbound protein. To detect the bound bCNTF, horseradish peroxidase (HRP)-
conjugated streptavidin was added to the wells and observed colorimetrically by 
measuring the optical density of the well solutions after incubation with 3,3’,5,5’-




4.2 In vitro bioactivity study (publication II) 
An in vitro cell study was carried out to verify that purified rhCNTF was active and 
able to trigger biological responses. CNTFRα expressing TF-1.CN5a.1 cells used in 
the experiments were maintained in a fully humidified 5% CO2 atmosphere at 37°C 
as suspension cultures in a modified RPMI 1640 growth medium supplemented with 
fetal bovine serum (FBS), human granulocyte macrophage colony-stimulating factor 
(hGM-CSF), G-418, and penicillin/streptomycin.  
The rhCNTF-mediated effects on TF-1.CN5a.1 cell proliferation was studied by 
measuring the incorporation of nucleotide analogue 5-bromo-2'-deoxyuridine (BrdU) 
during cell proliferation (Porstmann et al., 1985). First, serial dilutions of purified 
rhCNTF were prepared in assay growth medium (complete growth medium without 
hGM-CSF and G-418) and added to wells in 96-well microplates for suspension cells. 
Supplements were removed from cultured TF-1.CN5a.1 cells by centrifugation and 
washing, and after resuspension in assay growth medium the cells seeded at 1.0 x 104 
cells per well, yielding final rhCNTF concentrations ranging from 24 fg/ml to 100 
ng/ml. Cells cultured in assay growth medium with and without hGM-CSF were used 
as positive and negative controls, respectively. rhCNTF and control treatments were 
carried out for 48 h. 
After treatment, BrdU labeling solution was added and the cells were incubated 
to allow for incorporation of BrdU into the synthesized DNA during cell proliferation. 
After labeling, the cells were pelleted by centrifugation, the media aspirated from the 
wells, and the cells dried at 60°C, after which the cells were fixed and the DNA 
denatured with FixDenat solution. Followed by the removal of FixDenat solution, now 
allowing access to the incorporated and exposed BrdU, incubation with an HRP-
conjugated anti-BrdU antibody was carried out. After antibody solution removal and 
repeated washing, TMB substrate solution was added to the wells, resulting in a 
colorimetric change that was subsequently quantitated by measuring the well 
absorbances. 
4.3. Permeation of rhCNTF in ex vivo retinal explants (publication II) 
To investigate whether rhCNTF can permeate into the retina, experiments mimicking 
in vivo ocular drug administration were carried out with ex vivo organotypic retinal 
explants prepared from bovine and rat eyes.  
4.3.1 Fluorescent labeling of rhCNTF 
For rat retinal explant experiments, purified rhCNTF was fluorescently labeled with 
Alexa Fluor™ 488 via tetrafluorophenyl ester linkage, conjugating the fluorophores 
to available amines, such as the N-terminus and exposed lysine side chains. Unreacted 
dye was separated from labeled protein with spin filters and the degree of labeling 
analyzed spectrophotometrically. Labeled rhCNTF was stored on ice until use. 
For bovine retinal explant experiments, rhCNTF was fluorescently labeled with 
NT-647 via NHS ester linkage, likewise, to exposed amines. Unreacted dye was 
removed with spin columns and the degree of labeling analyzed 




4.3.2 Retinal explant culture preparation and rhCNTF treatment 
CD® (SD) IGS rat eyes were used to prepare ex vivo organotypic retinal explant 
cultures as described earlier (Arango-Gonzalez 2010, Caffe 2002). Young, 5, 6, or 8 
days old animals were euthanized, and the eyes enucleated aseptically. After cleansing 
with ethanol, the eyes were briefly incubated in basal R16 medium followed by 
incubation in 0.12 % proteinase K for 15 min at 37°C to facilitate dissecting. To 
inactivate proteinase K the eyes were subsequently incubated in basal R16 medium 
containing FBS, and finally washed in serum-free basal R16 medium.  
Dissections were carried out aseptically in a Petri dish with the eyes submerged 
in basal R16 medium. The anterior segment, sclera, choroid, lens and the vitreous body 
were delicately removed, leaving the retina with the attached RPE. Relaxing cuts were 
made and the retinae flat-mounted with the photoreceptor-side down on the porous 
culture membrane inserts i.e. at the air-medium interface. The cultures were 
maintained with complete R16 medium placed in the lower compartments of 6-well 
culture dishes at 36.5°C and 5% CO2. No antibiotics or antimycotics were used. 
Explants were left without treatment for 24 h to allow adaptation to culture 
conditions, followed by rhCNTF treatments for 24 h. Alexa Fluor™ 488-labeled 
rhCNTF was prepared in phosphate buffered saline (PBS), diluted in basal R16 
medium and sterilized with membrane filter before use. Treatments were either 
applied apically directly as drops on the explant cultures, or basolaterally in complete 
medium in the lower compartment to mimic dosing via IVT and e.g. subretinal 
injections, respectively. Complete R16 medium was used as control. 
Bovine retinal explant cultures were prepared as described earlier (Peynshaert 
et al., 2017). First, fresh bovine eyes were cleaned of periocular tissues and disinfected 
with immersion in ethanol. The eye was bisected below the limbus, the anterior 
segment and the vitreous removed, with the remaining posterior eye cup filled with 
CO2 independent medium and cut into 4 flaps. While submerged in medium, circular 
pieces of the retina were punched with a trephine blade and then transferred onto 
moisturized porous culture membrane inserts with the photoreceptor-side down. 
Explant culture medium supplemented e.g. with penicillin-streptomycin was added 
below the inserts and explant cultures maintained at 37°C and 5% CO2. Treatments 
were given directly after explant preparation, with NT-647-labeled rhCNTF applied 
as drops on top of explants, followed by incubation for 24 h. 
4.3.3 Tissue culture fixation and sectioning  
Treated rat explants were fixed in 4% paraformaldehyde (PFA). After a short 
incubation at 4°C, the fixative was changed to 1% PFA and incubated further at 4°C 
overnight. Retinae were then washed with PBS and cryoprotected by incubation in 
graded sucrose solutions. Subsequently, tissues were embedded, with the vertical 
sections obtained on a microtome first air dried at 37°C, and then stored frozen until 
use. 
Treated bovine explants were fixed by replacing the medium below the filter 
with 4 % PFA. After incubation at 4°C PFA was discarded and replaced with sucrose 
solution and incubated overnight at 4°C. Explants were snap-frozen in Tissue-Tek® 
O.C.T Compound using liquid nitrogen and sections cut from four different region of 




4.3.4 Culture staining and imaging 
To prepare tissue sections from rat retinal explants for imaging, frozen cryosections 
were first air-dried. Slides with fixed sections of retinal tissue were washed with PBS 
and then mounted. To visualize cell nuclei, counterstaining with 4’,6-diamidino-2-
phenylindole (DAPI) was carried out. 
To assess the localization of labeled rhCNTF, immunofluorescence staining was 
carried out. First, slides with fixed sections of retinal tissue were washed with PBS. 
After subsequent incubation with blocking buffer, slides were incubated with primary 
polyclonal antibody against Iba-1 overnight at 4°C. Next day, the slides were 
repeatedly washed with PBS and incubated with Alexa Fluor™ 568-conjugated 
secondary antibody. Slides were then incubated in DAPI diluted in PBS to visualize 
cell nuclei. Finally, slides were washed repeatedly with PBS, dried out, embedded 
with antifade reagent, and closed with cover glasses. 
To observe the penetration and assess the localization of labeled rhCNTF, 
mounted sections were imaged using a microscope equipped with a digital camera, 
and the acquired images from multiple explant areas subsequently manually inspected 
for the presence of fluorescence. 
 
Sections from bovine retinal explants were incubated for 1 h at room temperature in 
blocking buffer, followed by overnight incubation at 4°C with rabbit antibody against 
Collagen IV to assess ILM integrity. Next, sections were stained with Alexa Fluor™ 
488-labeled goat anti-rabbit secondary antibody, and to visualize cell nuclei, 
counterstained with Hoechst dye for 1 h at room temperature. 
Sections were mounted with Vectashield® and prepared for imaging. As before, 
mounted sections were imaged using a microscope equipped with a digital camera, 
and the presence of fluorescence assessed manually from multiple explant areas to 
observe penetration of labeled rhCNTF. 
4.4 Accelerated protein development (publication III) 
To construct a novel production platform for streamlined pharmaceutical protein 
development and bioconjugation, we integrated cell-free protein synthesis (CFPS) 
with Nostoc punctiforme DnaE split intein-mediated capture, and UV-light triggered 
release.  
4.4.1 Cell-free protein synthesis 
Various CFPS systems were utilized for recombinant protein production. Whereas 
lysates prepared from different E. coli cell strains and wheat germ extract were also 
tested, for hCNTF-NpuDnaEΔC16 production, CFPS systems utilizing tobacco plant 
bright yellow 2 cell lysates (BYL) (Buntru et al., 2015) and mammalian HeLa cell 
lysates (1-Step Human Coupled IVT kit; Thermo Fisher Scientific, USA) were 
utilized. Whereas in certain developed cell-free systems the in vitro transcription and 
translation reactions are carried out separately, both CFPS systems used here are 
supplemented with an RNA polymerase, coupling the transcription of the template 
DNA to mRNA with the translation of the mRNA to protein in the same system. 




energy substrates, as well as the accessory proteins and enzymes required in the energy 
metabolism, transcription, translation, and protein folding during recombinant protein 
synthesis. 
CFPS systems were used according to published protocols and manufacturer’s 
instructions. Briefly, CFPS of hCNTF-NpuDnaEΔC16 was carried out by first mixing 
the required reaction components, followed by addition of plasmid DNA template. 
Prepared BYL CFPS reactions were incubated at 25°C shaken for up to 20 h in 96-
well plates, whereas HeLa CFPS reactions were incubated stationary at 30°C for 6 h 
in microcentrifuge tubes. The quality of each CFPS reaction was checked by using 
enhanced green fluorescent protein (eGFP) as a positive control protein parallel to the 
CFPS reactions of the samples. Expression levels were also compared to a negative 
control where no template DNA was added to otherwise complete reaction mixtures. 
The synthesized target proteins in the complex CFPS matrix were used in subsequent 
experiments immediately without storage. 
4.4.2 Photocleavage of peptides 
To study the photocleavage of synthesized NpuDnaEC16 peptides, i.e. C-inteins with 
various incorporated linkers and conjugates (Table 5), peptide samples were dissolved 
in ultra-pure water and reduced with tris(2-carboxyethyl)phosphine (TCEP) at 27°C 
for 30 min and then exposed to UV365nm light for 0–30 min. 
 
Table 5. Synthesized NpuDnaEC16 peptides. Peptides with photoreactive groups marked in bold. 
 Peptide sequence Incorporated moieties 
PEP1 DGHNFALKNGFIASNCFGSKHis6 N/A 
PEP2 DGHNFALKNGFIASNCF-X-GSKHis6 X = F(2-NO2) = 2-Nitrophenylalanine 
PEP3 DGHNFALKNGFIASNC-X-GSKHis6 X = Fmoc-(S)-3-amino-3-(2-nitrophenyl)propionic acid 
PEP4 DGHNFALKNGFIASNCF-X-GSKHis6 X = Fmoc-photo-linker (CAS 162827-98-7) 
PEP5 DGHNFALKNGFIASNCGSG-X-GGHis6 X = Biotin on the side chain of lysine 
PEP6 DGHNFALKNGFIASNCGSG-XY-GGHis6 X = Biotin on the side chain of lysine Y = Photo-linker CAS 162827-98-7 
PEP7 DGHNFALKNGFIASNCGSG-XY-GGEPEA X = Biotin on the side chain of lysine Y = Photo-linker CAS 162827-98-7 
PEP8 DGHNFALKNGFIASNCGSG-X-Y-GSKHis6 X = Propargylglycine; Y = F(2-NO2) 
 
Generated peptide fragments were separated with an HPLC system and their elution 
monitored with UV216nm detection. The peptides were applied to a C18 (150 × 4.6 mm, 
5 μm) column maintained at 25°C and a flow rate of 1.5 ml/min was used for all 
separations. Samples diluted in water were injected into the column using water (A) 
and acetonitrile (ACN; B), both with 1% trifluoroacetic acid, as eluents. The same 
gradient program (0–14 min 1% → 40% B, 14–16 min 40% → 70% B, 16–16.1 min 
70% → 1% B, followed by 14 min equilibrium at 1% B) was used to elute all samples. 




under the curve (AUC) of the respective main peptide peak was used as a surrogate to 
measure light triggered cleavage of the peptides. 
4.4.3 Capture and release 
Having a pivotal role in the capture and release of expressed protein, the applicability 
of the intein-mediated protein trans splicing (PTS) of the artificially split NpuDnaE 
intein (NpuDnaEΔC16 / NpuDnaEC16) was studied.  
To verify that the association and auto-excision of the folding intein domain can 
indeed ligate flanking exteins, in this study 1) a C-terminal peptide sequence 
containing e.g. a photocleavable moiety and/or a purification tag to 2) expressed 
protein of interest, the following experiments were set up. PTS reactions between 
photocleavable PEP2 / PEP3 (Table 5) and CFPS reactions containing expressed 
hCNTF-NpuDnaECΔ16 in the CFPS reaction matrix were carried out for 3 h at room 
temperature. The resulting putative C-terminally His6-tagged hCNTF was captured 
with magnetic, Ni2+-beads; handling of the magnetic beads was carried out with a 
magnetic purification system (KingFisherTM, Thermo Fisher Scientific). Unbound 
proteins and CFPS reaction components were subsequently removed from the beads 
by repeated washing-steps. Photocleavage-mediated release of hCNTF was carried out 
with UV365nm light for 0–6 h. 
Utilizing the intein ligation reaction itself in the capture of the expressed protein 
was also evaluated. In this setup, PEP3 was first immobilized on the Ni2+-beads. PTS 
reaction between immobilized PEP3 and CFPS expressed hCNTF-NpuDnaEΔC16 was 
carried out overnight in room temperature to capture and immobilize the resulting 
ligation product, hCNTF-His6, on the magnetic beads. As before, unbound proteins 
and CFPS reaction components were removed by repeated washing, and the release 
of hCNTF carried out by photocleavage with UV365nm light for 0–6 h. 
To verify that the capture and release were indeed achieved via the intein-
mediated ligation and photocleavage, respectively, control experiments were carried 
out. A mock capture experiment was carried out using only the CFPS expressed 
hCNTF-NpuDnaEΔC16 to rule out non-specific binding to the beads. After repeated 
washing to remove unbound proteins and components of the CFPS reaction, ‘release’ 
was carried out by photocleavage with UV365nm light for 0–6 h. Similarly, to verify 
that the release takes place through cleavage of the photolabile groups, a mock release 
experiment was carried out. First, the non-photocleavable PEP1 was immobilized on 
the Ni2+-beads, followed by PTS reaction between immobilized PEP1 and CFPS 
expressed hCNTF- NpuDnaEΔC16 carried out overnight in room temperature, resulting 
in the immobilization of the ligation product, hCNTF-His6, on the magnetic beads. 
After removal of unbound proteins and components of the CFPS reaction by wash 
steps, ‘release’ of hCNTF was carried out by photocleavage with UV365nm light for 0–
360 min. 
As described in detail in publication III, detection of expressed, captured and 






PTS reactions were carried out between CFPS expressed hCNTF-NpuDnaEΔC16 and 
NpuDnaEC16 PEP1, PEP5, PEP6 or PEP7 (Table 5). First, to assess if the respective 
modifications affect the PTS reaction, for example through steric hindrance, the 
biotinylated PEP5, PEP6 and PEP7 were used, whereas the non-modified PEP1 was 
used as a positive control for the PTS reaction. Briefly, HeLa CFPS reaction matrix 
containing expressed hCNTF-NpuDnaEΔC16 was mixed with PEP1, PEP 5, PEP6 or 
PEP7 (all pre-reduced with TCEP) and the PTS allowed to take place in room 
temperature for 2 h. Reactions were halted with the addition of Laemmli sample 
buffer. 
In a similar setup, to verify transferring biotin onto the protein of interest via 
PTS, the biotin-carrying PEP5 was used whilst PEP2 was used as a negative control. 
PTS reactions between these peptides and CFPS expressed hCNTF-NpuDnaEΔC16 
were set up as described above and carried out at room temperature overnight. Taking 
advantage of the strong, SDS-resistant binding between streptavidin and biotin, a 
streptavidin gel-shift assay (adapted from Fairhead and Howarth ADD and Sorensen) 
was used to visualize the transfer of biotin moiety to hCNTF. The described PTS 
reactions yielding the putative non-biotinylated and biotinylated hCNTF products 
were mixed with streptavidin, and the streptavidin-biotin binding then allowed to take 
place for 3 hours in room temperature. WB was carried out to detect protein expression 
and to determine the impact of biotinylation and streptavidin-binding on the 





5 Study I: Codon optimization and factorial screening 
for enhanced soluble expression of human ciliary 






































Reprinted with permission from Itkonen, J.M., Urtti, A., Bird, L.E., Sarkhel, S., 
(2014). Codon optimization and factorial screening for enhanced soluble expression 
of human ciliary neurotrophic factor in Escherichia coli. BMC Biotechnology, 14: 92. 




6 Study II: Characterization and stability studies of 
recombinant human CNTF and its permeation in the 













































7 Study III: Accelerated pharmaceutical protein 
development with integrated cell free expression, 






































Reprinted with permission from Richardson, D., Itkonen, J., Nievas, J., Urtti, A., 
Casteleijn, M.G., (2018). Accelerated pharmaceutical protein development with 
integrated cell free expression, purification, and bioconjugation. Scientific Reports, 8: 




8 Summary of the main results 
The central findings of the publications are described in the following sections. 
Detailed results are found in the original publications.  
8.1 Soluble expression of rhCNTF in E. coli (publication I) 
To account for codon usage bias, a recognized obstacle with heterologous protein 
expression in foreign hosts, the hCNTF gene was codon optimized for expression in 
E. coli.  To pinpoint suitable conditions for the soluble expression of rhCNTF, among 
E. coli bacterial cell strains and culture conditions, different fusion partners for 
enhanced protein solubility/folding were also included into the screening. PCR-
amplified gene inserts and restriction enzyme-linearized plasmids were used to 
construct 9 different expression plasmids using Gibson AssemblyTM. After blue/white-
screening of colonies, the incorporation of the hCNTF gene was confirmed via PCR 
using tag- and insert-specific primers. After propagation of the positive clones, the 
plasmid DNA was purified with Mini-preps and stored at -20°C for later use. 
Screening of soluble expression was carried out in a total of 54 different 
combinations of culture conditions, culture media, bacterial cell strains, and fusion 
partners; rhCNTF overexpression was notably observed in all screened expression 
condition combinations.  
To increase production of soluble rhCNTF for future experiments, expression 
was scaled up using pOPINF-hCNTF construct with autoinduction media, TBONEX 
at 25°C. After purification, 112 mg of soluble rhCNTF per ml culture medium was 
obtained, an 8- to 9-fold increase in soluble fraction and 10- to 20-fold increase in 
overall yield compared to earlier published reports. The function – and indirectly the 
correct folding – of purified rhCNTF was verified in an ELISA binding assay with the 
cognate receptor CNTFRα, with an estimated EC50 of 36 nM. 
In summary, codon optimization combined with screening of expression 
conditions identified numerous conditions for producing soluble, functional rhCNTF. 
Generally, this approach is attractive for the high throughput expression screening of 
(pharmaceutically relevant) proteins. 
8.2 rhCNTF characterization and stability (publication II) 
Circular dichroism was utilized to study the structure of purified rhCNTF. As observed 
in the obtained spectra, a highly α-helical secondary structure and thus correct folding 
of rhCNTF was confirmed. 
To ensure that the purified rhCNTF was not just able to bind to its cognate α 
receptor, but also biologically active and able to trigger downstream signaling, an in 
vitro cell-based study was carried out. Observed as BrdU incorporation, rhCNTF 
supported the short-term proliferation of the CNTFRα expressing cell-line TF-
1.CN5a.1 with an estimated EC50 of 19 pg/ml (0.8 pM). 
As previously used phosphate-buffered rhCNTF formulation showed a 
considerable loss of active protein upon freeze-thawing, buffer optimization was 
carried out using differential scanning fluorometry, also known as ThermoFluor, to 




increased thermodynamic stability upon heating, elevated Th was observed in several 
screened buffer, salt, and pH conditions, identifying potential storage conditions for 
rhCNTF. Out of the several potential formulations, clear fluorescence responses and 
high Th estimates were observed with 100 mM sodium citrate, pH 5.6 and 100 mM 
MES, 500 mM NaCl, pH 7.0, reflecting high thermal stability. These formulations 
were chosen for follow-up studies.  
Conformational stability of rhCNTF was retained in both buffers during storage 
on ice at +4°C and frozen at -80°C. Small amounts of high molecular weight species 
were detected in both storage conditions in the MES-based formulation, whereas only 
negligible amounts were found in the citrate formulation. No apparent loss of protein 
upon freeze-thawing was observed in either buffer. 
In summary, we verified that expressed and purified rhCNTF was properly 
folded and biologically active. Screening identified buffer formulations enhancing 
rhCNTF stability, which can be used as a basis for further development through 
screening of e.g. additives to further improve the stability of rhCNTF. 
8.3 Retinal permeation of labeled rhCNTF (publication II) 
To investigate whether rhCNTF can permeate the retina to reach target cells, 
experiments with ex vivo organotypic retinal explants prepared from bovine and rat 
eyes war carried out to imitate in vivo ocular administration of the protein. 24 h after 
apical application – imitating intravitreal administration – labeled rhCNTF penetrated 
the inner limiting membrane and permeated further into the neural retina in 
organotypic ex vivo retinal explants prepared from both bovine and rat eyes. Studied 
only on explants from rat eyes, permeation into the retina after basolateral application 
– imitating periocular administration – was not observed. Seen as co-localization with 
Iba-1 immunopositivity, rhCNTF permeation to retinal microglia was observed. The 
labeled protein’s permeation to retinal layers with CNTFRα expressing cells supports 
the possibility for direct neuroprotective actions. More generally, the ex vivo retinal 
explants have potential use in the systematic evaluation of the underlining 
determinants and factors of intravitreal biologicals’ retinal permeation. 
8.4 Accelerated protein development (publication III) 
NEBuilder® was used to construct expression plasmids from PCR-amplified target 
protein genes and inverse PCR-amplified vector backbones for recombinant protein 
expression in BYL and HeLa-based CFPS. The insertion of target protein genes was 
first assessed with colony PCR, followed by verification with DNA sequencing. After 
propagation, plasmid DNA was purified with Midi-preps and stored at -20°C for later 
use.  
The protein of interest, rhCNTF-NpuDnaECΔ16, was expressed in both BY-2 and 
HeLa CFPS systems with yields of 20 mg/ml and 49 mg/ml, respectively. The protein 
trans splicing reaction was observed to yield C-terminally tagged target protein, 
verifying that upon association and folding, the cleavage of the auto-catalytic intein 
domain does take place in the complex CFPS matrices. 
The efficiency and rate of light triggered photocleavage of the synthesized 




cleavage of less complex peptides was highest with PEP3 and PEP4, and lowest with 
PEP2, whereas with the bulkier peptides highest with PEP6 and PEP7, and lowest with 
PEP8 (Table S3). In general, rate of cleavage was slower with the bulkier peptides. 
Whether utilizing the NpuDnaEC16 peptide immobilized on a solid support or 
first in solution to generate the de novo affinity-tagged target protein, the PTS reaction 
with CFPS expressed rhCNTF-NpuDnaECΔ16 yielded His6-tagged rhCNTF captured 
on magnetic Ni2+-beads. With the photocleavage-mediated release of rhCNTF to our 
chosen formulation, all included steps were completed in under 24 h, providing a 
proof-of-concept for our developed platform for streamlined protein production. 
Furthermore, moieties incorporated in the synthesized C-intein peptides were not 
observed to disrupt the PTS reaction and PTS successfully transferred biotin from 
PEP5 to rhCNTF as seen via binding to streptavidin. 
In summary, a proof-of-concept was provided for our developed platform integrating 
split intein-mediated capture, light triggered release, and bioconjugation, shown as 
streamlined production of model protein hCNTF. The platform may have potential 






After the first biological, Humulin®, was granted market approval in the early 1980’s, 
hundreds of different biologicals have since been developed and used for treating 
different diseases. Biologicals are the fastest growing class of pharmaceuticals and are 
in widespread use in various fields of medicine today. In ophthalmology, anti-VEGF 
biologicals, such as ranibizumab, bevacizumab, and aflibercept, have become standard 
treatments for wet AMD and DME, diseases featuring pathological growth of 
abnormal blood vessels. Whereas anti-VEGF therapies are effective in most patients, 
in certain cases, drug response declines over time and some patients fail to respond 
altogether (Yang et al., 2016). Furthermore, as these IVT injected biologicals have 
limited intraocular half-lives, their effects are only transient. Successful anti-VEGF 
therapy therefore commonly requires long-term follow-up, repeated administration, 
and commitment to the planned treatments. It is unsurprising that patient compliance 
with these treatments is sub-optimal. Thus, longer acting treatments circumventing or 
at least allowing for less frequent IVT dosing are in great demand and are actively 
pursued in biological drug development. 
With the several anti-VEGF biologicals currently in development, new 
treatments for neovascular diseases will most likely emerge. Non-angiogenic posterior 
eye segment diseases, however, still suffer from a lack of effective treatments, 
especially such that would target disease pathogenesis. Moreover, as the number of 
AMD patients is projected to increase from 196 million to 288 million between 2020 
and 2040 globally (Wong et al., 2014), and as in the US the prevalence of retinal 
diseases is expected to more than double between 2010 and 2050 (Fig. 8), there is 
great urgency to develop new treatments for these diseases. 
 
 
Figure 8. Prevalence of most common retinal diseases causing vision loss and legal blindness in the US. Data and 
projections obtained from National Eye Institute website https://nei.nih.gov/learn-about-eye-health/resources-for-
health-educators/eye-health-data-and-statistics. 
Ever since the pioneering work of Rita Levi-Montalcini and her peers it has been 
widely perceived that neurotrophic factors hold immense promise as potential 
therapies against neurodegenerative diseases. However, rapid enzymatic clearance 
and physiological barriers present formidable obstacles to delivering (neuroprotective) 




























in the back of the eye, a region of the CNS more readily accessible for local drug 
delivery, represent attractive targets for neuroprotective factors (Pardue & Allen, 
2018). Furthermore, as degeneration of different retinal neurons is a common feature 
of most posterior segment diseases regardless of disease etiology, neuroprotective 
therapeutic approaches are considered more universally applicable. 
Much to the chagrin of patients and research community, various obstacles have 
hampered the progress to develop neuroprotective biologicals for ophthalmic use. Of 
the many proteins with recognized neurotrophic potential, none have yet translated 
from preclinical research to available treatments for posterior segment diseases nor 
any other neurodegenerative diseases. As abundant obstacles and open questions 
remain in the way of harnessing the potential of these and many other therapeutically 
potential proteins, there is ample room for innovation and improvements. This thesis 
focused on different protein production and development approaches while also 
touching on the pharmacokinetics, and in particular the retinal permeation of 
ophthalmic biologicals using human CNTF as an ophthalmologically relevant model 
protein. In the following sections, the used methods and obtained results and their 
implications will be discussed. 
9.1 Therapeutic protein production and development 
Production. The production of high protein quantities can be a significant roadblock, 
especially during the early stages of biological drug research and development. 
Considerable efforts are put into addressing the involved obstacles by developing and 
improving methods and techniques for protein expression and purification. However, 
as each protein can be considered unique, oftentimes also in their production, 
therapeutic protein production workflows are designed and developed in part as 
dictated by the protein. In other words, although drug developers and researchers have 
a wide and growing palette of different tools at their disposal, in order to meet the 
requirements of individual proteins, considerable process customization and 
optimization is commonly necessary, and often determined empirically (Berkmen, 
2012).  
Recombinant protein production can be carried out in different expression hosts 
ranging from simple bacteria and yeast to considerably more sophisticated insect, 
plant, and mammalian systems (Singha et al., 2017). Even though the available 
systems differ vastly, for example, in their costs, complexity, speed, and achievable 
yields, the choice is not only dependent on these ‘external’ factors. For example, 
overexpression of heterologous recombinant proteins in the simplest system, E. coli, 
often takes place in a microenvironment alien to the target protein (Rosano & 
Ceccarelli, 2014). This can also overwhelm the host’s intracellular protein folding and 
proteostasis machinery, leading to the expressed protein accumulating as insoluble 
inclusion bodies (Singha et al., 2017). Complicated refolding is necessary for 
purifying soluble recombinant protein from inclusion bodies, and as this may still yield 
protein in a misfolded and aggregation prone state (Gąciarz et al., 2017; Sarker et al., 
2019), potentially leading to immunogenicity (Thatcher, 1990), avoiding inclusion 
body formation is highly desirable. Moreover, E. coli is limited in its capacity to form 
PTM’s such as disulfide bonds correctly (Berkmen, 2012; Gąciarz et al., 2017) and it 




features can be critical for many properties of proteins, such as proper folding, activity, 
stability, and pharmacokinetics, the requirements for the expression host are critically 
important and dictated by the properties of an individual protein. For example, 
glycosylated mAbs require expression in PTM-competent mammalian hosts, and as 
they comprise the majority of biologicals in development, mammalian-based systems 
(e.g. CHO cells) have become prominently used (Walsh, 2018). 
Regardless of its shortcomings, using E. coli for recombinant protein expression 
is desirable owing to its notable advantages. As it has been utilized for decades, the 
use of E. coli is well established with plenty of available resources and tools. 
Furthermore, E. coli can be rapidly cultured, easily handled and its genetic 
manipulation is well-established. Since it is also cost-effective, E. coli is often a first 
choice as a protein expression host (Berkmen, 2012; Rosano & Ceccarelli, 2014; Jia 
& Jeon, 2016). E. coli is currently utilized in the production of around 30% of 
biologicals on the market (Singha et al., 2017). 
As the correct parameters for protein expression are difficult to predict, 
producing high protein yields is often a trial and error process (Berkmen, 2012). 
Therefore, in setting up a production pipeline for a protein of interest, small-scale 
testing of several expression hosts, expression constructs, and culture conditions has 
become a commonly adopted strategy to aid in selecting the most favorable conditions. 
As rapid progress is made in this field, reviews discussing ‘try-first’ strategies and 
approaches for enhancing recombinant protein production have been compiled (Peti 
& Page, 2007; Gräslund et al., 2008; Rosano & Ceccarelli, 2014; Jia & Jeon, 2016; 
Singha et al., 2017). 
The manufacture of cytokine therapeutics can be challenging (Lipiäinen et al., 
2015). Although these proteins have been studied since the late 1970’s, many efforts 
to produce the neuropoietic cytokine hCNTF in E. coli resulted in low yields and/or 
required protein purification and refolding from insoluble inclusion bodies (Krüttgen 
et al., 1995; McDonald et al., 1995; Di Marco et al., 1996; Narhi et al., 1997; Wagener 
et al., 2014). Here, by utilizing codon optimization and screening of different factors, 
such as culture media, solubility enhancing fusion tags, and bacterial strains, we found 
suitable conditions for the expression of soluble rhCNTF in E. coli. These conditions 
were later utilized in production scale-up to produce high amounts of functional 
rhCNTF (publication I). Whereas the functional activity of purified rhCNTF was first 
indirectly verified through binding with the cognate alpha receptor (publication I), the 
correct folding and biological activity were later observed with circular dichroism and 
in a cell proliferation assay, respectively (publication II).  
 
Stability. The environmental conditions that biologicals experience during 
production, i.e. synthesis in living cells, purification and formulation, are very 
different compared to their native environments. During these processes, biologicals 
are exposed to both chemical and physical stresses that can affect the conformational 
stability of the proteins; compared to the native milieu and conditions the changes in 
the protein environment can be considerably more dramatic during production. These 
stresses may perturb the native state, ultimately resulting in partial or complete 
unfolding of the protein structure. As protein functionality depends on its 
conformation and stability, the structural denaturation can lead to diminished or lost 




degradation and denaturation include physical factors (e.g. pressure, shear stresses, 
temperature) and chemical changes (e.g., oxidation, deamidation, disulfide 
modifications, fragmentation) (Manning et al., 2010; Jiskoot et al., 2012; 
Radhakrishnan et al., 2017). Formation of protein aggregates is another common 
outcome from structural unfolding. The aggregation results from de novo interactions 
between newly exposed protein regions.  
Aside from its production challenges, in vitro CNTF is not stable at room and 
body temperature (Hottinger & Aebischer, 1999; Fandl et al., 2006). For example, 
decreased solubility and increased propensity to aggregate upon unfolding have been 
observed with hCNTF (Narhi et al., 1997). Furthermore, covalent dimer formation via 
unpaired cysteine residue has been proposed to lead to hCNTF aggregates and 
precipitation (Fandl et al., 2006). More generally, the manufacture of cytokine 
therapeutics is often challenging due to their propensity to aggregate and adhere to 
surfaces, which is postulated to arise from their hydrophobicity (Lipiäinen et al., 
2015), an attribute of cytokines’ helical bundle fold (Ricci & Brems, 2004). It is 
reasonable to assume that such attributes also play a role in the stability of the similarly 
folded hCNTF. To this end, modifications to CNTF’s structure have been made to 
generate variants with improved therapeutic activity, but also improved solubility and 
stability (Panayotatos et al., 1993; Fandl et al., 2006). In our study, phosphate-based 
storage formulation was not suitable for purified rhCNTF, resulting in significant loss 
of protein upon freeze-thawing. Therefore, we had to find a more suitable liquid 
formulation. 
A wide variety of analytical methods can be utilized to characterize proteins and 
to assess their stability (den Engelsman et al., 2011; Jeong et al., 2012; Filipe et al., 
2013). Here, a spectrum corresponding to a highly helical protein was first observed 
with circular dichroism (CD), confirming the correct folding of produced rhCNTF 
(publication II). Whereas low-throughput methods such as CD and differential 
scanning calorimetry can be used to assess proteins’ conformational stability, we 
wanted to do this with rhCNTF’s in numerous formulations, and therefore opted to 
use differential scanning fluorimetry as it is amenable for higher throughput (Filipe et 
al., 2013). This method, more commonly known as ThermoFluor, is a thermal shift 
assay that measures thermal unfolding of proteins using different fluorescent dyes as 
reporters (Kopec & Schneider, 2011; Sviben et al., 2018). Commonly used fluorescent 
dyes, such as SYPRO Orange® and bis-ANS, bind to hydrophobic residues and 
regions in proteins. In an aqueous environment their fluorescence is quenched, but 
upon increasing environment hydrophobicity (e.g. during thermal protein unfolding), 
the dyes are consequently able to fluoresce upon interacting with exposed hydrophobic 
regions, leading to dramatic increases in the fluorescence signal (Pantoliano et al., 
2001; Boivin et al., 2013). The temperature of hydrophobic exposure (Th) can be 
derived from the obtained fluorescence signal in this indirect measurement of 
unfolding; Th correlates well with the melting temperature, Tm, observed with 
orthogonal methods (Seabrook & Newman, 2013). ThermoFluor has other 
applications in drug discovery (Pantoliano et al., 2001), optimization of protein 
purification, characterization (Boivin et al., 2013), crystallization (Sviben et al., 
2018), protein stabilization (Seabrook & Newman, 2013), and in assessing the 
formation and stabilization of protein-protein complexes (Kopec & Shneider, 2011). 




specific dyes that react with accessible cysteines upon unfolding and dyes for 
monitoring of protein aggregate formation have been developed (Boivin et al., 2013). 
Here, we utilized SYPRO Orange® in a ThermoFluor screen with various 
buffer, salt, and pH conditions to determine changes in the Th and conformational 
stability of rhCNTF (publication II). Based on the screen, two buffers with high Th 
estimates were chosen for rhCNTF storage. The protein’s storage stability was 
subsequently monitored with ThermoFluor and dynamic light scattering (DLS); 
whereas ThermoFluor was used to monitor for changes in the Th, DLS was utilized to 
detect higher molecular weight species, such as protein aggregates. In DLS, the rate 
of scattering fluctuations over time are measured; as these scattering rate fluctuations 
relate directly to diffusivities and hydrodynamic size, DLS can be used to assess the 
presence of particles of different sizes, such as protein aggregates, in liquid 
formulations (Philo, 2009). However, DLS is not quantitative, cannot distinguish 
between species of similar sizes, and is fairly inaccurate with non-spherical species. 
Therefore, it is most suited for rapid screening for the presence of aggregates (Philo, 
2009; den Engelsman et al., 2011; Filipe et al., 2013). In general, it is recommended 
that different orthogonal methods, such as analytical ultracentrifugation and size-
exclusion chromatography are utilized for more detailed characterization of 
aggregates in protein formulations. 
Based on observed thermal stability and negligible amounts of formed 
aggregates, the citrate buffer appears to be the optimal formulation for further 
development of rhCNTF (publication II). As the presence of even trace protein 
aggregates can be critical risk factors for patient safety (Jiskoot et al., 2012), a more 
thorough analysis and characterization of aggregation is warranted, and further 
development should also focus on elimination of any aggregation in the CNTF 
formulation(s). Additionally, albeit based on preliminary observations rhCNTF 
remains stable in isolated vitreous at 37°C for 44 h (data not shown), post-
administration aggregation in oculo cannot be ruled out without further studies. 
Cell-free expression. Producing therapeutic proteins with cell-free protein synthesis 
(CFPS) is compelling as these systems offer numerous advantages over traditional 
cell-based expression systems (Casteleijn et al., 2013; Khambhati et al., 2019). For 
example, with the need for cell lysis removed, CFPS systems are rapid, open and more 
flexible, and they can facilitate the expression of toxic and difficult-to-express proteins 
while also allowing the incorporation of unnatural amino acids that can be utilized in 
bioconjugation and protein engineering. On the other hand, there are notable 
challenges that limit further use of the systems. As lysate preparation disrupts the 
cellular machinery that is needed for proper glycosylation patterns, CFPS systems are 
limited in their ability to perform this PTM. Despite considerable cost reductions 
achieved over the decades, CFPS is still costly compared to alternative protein 
expression systems (Casteleijn et al., 2013; Gao et al., 2019; Khambhati et al., 2019); 
for example, expressing rhCNTF yields comparable to those achieved in E. coli 
(publication I) with the commercial HeLa-cell based system would have required a 
budget in excess of 1 million euros. Based on recent marketing approvals the 
biopharmaceutical industry’s interest in CFPS is still to be invoked; instead of 
exploring, developing, and adopting new systems, tried-and-true expression hosts are 




scales may not yet be universally feasible with CFPS (Gao et al., 2019), as many of 
the recognized issues and shortcomings are being addressed, these systems are 
evolving rapidly (Castleijn et al., 2013; Khambhati et al., 2019). As such, they are far 
from reaching their full potential, and they can be expected to become alternatives and 
even replacements to cell-based systems for the production of biologicals in the future. 
Here, the expression of ophthalmologically relevant neurotrophic proteins CNTF 
(publication III) and PEDF (data not shown) was achieved using CFPS. 
Whereas state-of-the-art protein production in cells typically involves numerous 
downstream and upstream process steps and can take from weeks to months, here we 
described a potential integrated platform for streamlined production/screening of 
biologicals. We provided a proof-of-concept for our solution integrating CFPS with 
intein-mediated capture and UV-light release using rhCNTF as a model protein 
(publication III; Fig. 9). Moreover, transfer of biotin to the target protein was achieved 
with our system.  
    
Figure 9. Diagram of the integrated protein production workflow. (A) Cell-free protein synthesis of the protein of 
interest (POI) fused with a C-terminal NpuDnaECΔ16 N-intein (yellow); (B) Protein trans splicing (PTS)-mediated 
capture of POI. The synthesized NpuDnaEC16 C-intein capture peptides (orange-(purple)-red-blue) are either in 
solution or immobilized to a surface (latter scenario depicted). The red, purple, and blue segments represent a 
photo-cleavable amino acid/linker, an unnatural amino acid linked to a reactive moiety, and an affinity tag, 
respectively. At this stage the split intein will autocatalytically splice itself out upon folding; (C) After PTS, the 
cell-free expression matrix and side products are removed and the final buffer/formulation added; (D) UV-light 
triggered release of POI. Bioconjugation with the reactive moiety may be carried out with immobilized POI after 
stage C, with released POI after stage D, or even later. 
At this stage our aim was to condense and streamline protein production times to a 
fraction of the time compared to traditional approaches, as described, for example, in 
our production workflow with E. coli cells (publication I). Therefore, we did not assess 
the folding or activity of the purified rhCNTF, nor did we study whether the release 
with high energy UV light had any detrimental effects on the protein. As such, the 
described work was the first step of a planned platform with integrated analytical 
instruments and modules for measuring and monitoring, e.g., the amount, activity, 
integrity, and immunogenicity of expressed proteins. Additionally, as the platform can 
be used for the directed bioconjugation of proteins, the concept might be expanded by 
utilizing alternative inteins, peptides, and incorporated moieties to open further 
possibilities for protein engineering. For example, better control over glycosylation, 
PEGylation, and conjugation of other probes could be achieved as the number and 





9.2 Retinal penetration of biologicals 
Certain aspects in the ocular pharmacokinetics of biologicals are still poorly 
established. Whereas several recent studies have elucidated how different molecular 
attributes influence the vitreous half-life of biologicals (Shatz et al., 2016; Crowell et 
al., 2019), the picture on retinal permeation and posterior elimination of biologicals is 
less clear. Studies done with different biologicals and other macromolecules have 
given rise to varying and at times contradicting propositions for the determinants and 
limiting factors of retinal permeation. 
Whereas molecular weight (Mr) was initially proposed as the major determinant 
(Mordenti et al., 1999), this has later been disputed as permeation of the full retinal 
thickness has been observed with several biologicals larger than the proposed 
exclusion limits (El Sanharawi et al., 2010). Retinal permeation is considered to 
depend on the retinal anatomy and physiology as well as on the molecular attributes 
of individual biologicals (e.g.  molecular weight, charge, hydrophobicity, and 
hydrodynamic size) (El Sanharawi et al., 2010; Balaratnasingam et al., 2015). 
Interestingly, as unequal retinal penetration has been observed with biologicals of 
similar sizes (Shahar et al., 2006; Heiduschka et al., 2007), it is likely that retinal 
penetration does not depend only on size nor mere passive diffusion. Both binding 
specificities and active transport mechanisms have been postulated to influence retinal 
permeation of protein drugs (El Sanharawi et al., 2010). The influence of the proposed 
factors have, however, mostly been speculated, and any systematic quantitation of 
their contributions is yet to be carried out. As such, research on the retinal penetration 
of biologicals has predominantly been carried out with qualitative methods (e.g. 
immunohistochemistry, microautoradiography) and there are still sparse quantitative 
estimates of the retinal penetration of biologicals (del Amo et al., 2017). Moreover, 
retinal permeation studies with biologicals have most often been done with animal 
eyes and, therefore, translational value to the diseased human eyes remains uncertain 
(Eng & Kertes, 2006). 
Ophthalmic biologicals with smaller molecular weights and hydrodynamic sizes 
have been developed, since they can be formulated at higher molar doses. It is also 
assumed that smaller biologicals would permeate into the retina more efficiently. 
However, it is unclear how deep biologicals need to penetrate into the retina to achieve 
therapeutic activity. Since, for example, anti-VEGF biologicals may elicit their action 
by binding extracellular VEGF outside the retina (del Amo et al., 2017), it is not 
certain whether retinal penetration is in fact a requirement with all modalities. Clearly, 
regardless of their increasing use in treating ocular conditions, the retinal permeation 
of biologicals is poorly studied and inadequately understood. There are substantial 
gaps in our understanding of the underlying factors and their significance in retinal 
penetration. 
To our knowledge, no reports on the retinal penetration of the small protein 
CNTF (nor its engineered analogue Axokine®) have been published to date. Here, we 
utilized organotypic ex vivo retinal explant cultures to study retinal permeation with 
purified, labeled rhCNTF (publication II). We showed that rhCNTF readily permeates 
across the ILM and distributes into the neural retina. Even though ILM has been 
suggested to be an obstacle for intravitreal CNTF therapy (Müller et al., 2009), it did 




The main benefit of using such organotypic cultures is that in comparison to e.g. 
in vitro cell cultures and primary cell cultures, the intricate structure and cell 
connections of the retina are retained and the explants better reflect the in vivo situation 
(Valdés et al., 2016; Alarautalahti et al., 2019). Since there are anatomic differences 
between the eyes of different species (Peynshaert et al., 2017), retinal explants 
prepared from both rat and bovine eyes were used in this study for comparison. 
However, as the structure of the retina has been observed to change upon aging and 
degeneration, retinal permeation in such situations may be altered and should ideally 
be studied with models that better reflect this. Considerable differences depending on 
pathologies, disease stage and severity may, however, make disease effects 
challenging to study. Nonetheless, on one hand a possible limitation of our study is 
that the experiments were done with retinas obtained from healthy animals and the 
results may therefore not reflect permeation in pathological conditions nor in aged 
retinas. On the other hand, PK studies in healthy animals are considered valid as 
evidence points to disease effects in fact being insignificant, (del Amo et al., 2017), 
and studies utilizing explants from healthy eyes should therefore be valid.  
In a similar fashion with recent studies evaluating the influence of different 
factors on the intravitreal pharmacokinetics of biologicals (Shatz et al., 2016; Crowell 
et al., 2019), we see that the retinal explants have potential to be utilized in 
systematically evaluating the determinants of retinal permeation and further in 
developing biologicals capable of overcoming the various barriers therein. Based on 
preliminary observations in rat retinal explants, we have also seen penetration past the 
ILM into the neural retina with a set of other small model proteins (data not shown). 
9.3 Retinal effects and delivery of CNTF 
Retinal effects. Supportive and neurotrophic actions of CNTF against retinal damage 
and neurodegeneration have been demonstrated in several studies with different 
animal disease models (MacDonald et al., 2007; Wen et al., 2012). Although the 
protein has been widely studied for decades now, the exact molecular mechanisms of 
its neuroprotective actions on retinal neurons are still not fully understood. Whereas 
observed to elicit neuroprotection on different retinal neurons in vitro, this is 
considered to mostly occur indirectly, by modulating retinal glial cells to a more 
neuroprotective phenotype and inducing them to express and release other 
neuroprotective factors (Wen et al., 2012). 
Perhaps the most accepted theory is the so-called Müller hypothesis, in which 
the effects of CNTF in the retina are proposed to be mediated by inducing Müller glia 
– cells that envelop retinal neurons and provide them metabolic and homeostatic 
support – to express and secrete cytokines that elicit neuroprotection on 
photoreceptors and other cells (Rhee et al., 2013). CNTF treatment leads to activation 
of JAK-STAT and MAPK cascades in Müller cells both in vitro (Sarthy et al., 2016) 
and in vivo (Peterson et al., 2000), and induces extensive transcriptional changes in 
vivo, involving cytokines and growth factors (Xue et al., 2011). Interestingly, 
induction of both pro- and anti-inflammatory agents was detected in flow-sorted 
Müller cells after IVT administration of CNTF (Xue et al., 2011). Such widespread 
response may account for the complex effects that CNTF elicits on retinal neurons. 




treatment demonstrated efficacy in a phase II trial in patients with MacTel 2, a 
condition associated with Müller cell abnormalities and dysfunction (Wubben et al., 
2018). 
Apart from observed effects on Müller glia, CNTF may also modulate retinal 
astrocytes to adopt a more neuroprotective phenotype (van Adel et al., 2005). 
Furthermore, in vitro, the effects of exogenous CNTF on RGCs were observed to be 
mediated partially via the induction of endogenous CNTF expression in astrocytes 
(Müller et al., 2009), which have also been identified to be a major source of factors 
mediating the beneficial effects of inflammation in the eye (Leibinger et al., 2009). 
Although incompletely studied, it is possible that CNTF has similar effects on 
the third retinal glial cell type, microglia. These resident macrophages of the retina are 
commonly regarded to possess dual roles, being able to elicit both detrimental and 
protective effects on neurons (Wang et al., 2011; Rathnasamy et al., 2019). On one 
hand, they can support cell survival and repair by secreting growth factors, and on the 
other hand they can participate in inflammation by secreting pro-inflammatory 
cytokines, such as TNF-α and various interleukins, as seen in the retina. Although 
microglia-mediated inflammation is increasingly linked to retinal neurodegeneration, 
there is also evidence supporting a neuroprotective role of microglia (Karlstetter et al., 
2015; Rashid et al., 2019). Therefore, how retinal microglia affect neurons and their 
survival may strongly depend on context.  
Microglia are increasingly thought to play a central part in the pathophysiology 
of several retinal diseases (Karlstetter et al., 2015; Rashid et al., 2019), and activation 
and accumulation of retinal microglia have been observed, for example, in DR 
(Cunha-Vaz et al., 2014), AMD and RP (Glybina et al., 2010). Additionally, 
microglial activation and migration to the outer retina and subretinal space has been 
observed with age, possibly in response to local inflammation and tissue insults in the 
retina (Chen et al., 2010). Thus, modulation of microglia, and the glia-glia network 
by-and-large, has been studied as a therapeutic strategy for mitigating retinal 
neurodegeneration and inflammation (Rashid et al., 2019; Rathnasamy et al., 2019). 
For instance, sustained delivery of a low-dose corticosteroid markedly inhibits 
microglial responses (Glybina et al., 2010). As microglia have dual roles, modulating 
their action for neuroprotection is a complex task, requiring careful balancing; whereas 
microglial suppression may prevent the detrimental effects, simultaneous suppression 
of their neuroprotective action is unwanted and should be carefully evaluated in any 
therapy with microglial targets (Harada et al., 2002; Rashid et al., 2019) 
The direct role of CNTF on microglia and its effects on the crosstalk with Müller 
cells and the glia-glia and glia-neuron interactions (Harada et al., 2002; Wang et al., 
2011) are still unclear. Nonetheless, although to the best of our knowledge neither 
CNTFRα expression nor responses to CNTF have been studied in human retinal 
microglia, both are plausible. Direct effects on retinal microglia are supported here as 
labelled rhCNTF permeated into the retina and co-localized with microglia in the rat 
retinal explants (publication II), and as microglial responses to exogenous rat CNTF 
treatment have been observed in rat eyes (Cen et al., 2007). Furthermore, in terms of 
morphology and function, retinal microglia are comparable to their counterparts in the 
brain (Rathnasamy et al., 2019) and CNTF has been shown to influence CNS 
microglia in rodents, with CNTFRα expression observed in cultured primary 




and in human CNS microglia (Baek et al., 2018). Rat CNS microglia expressed and 
secreted trophic factors in response to CNTF (Krady et al., 2008), whereas in murine 
CNS microglia the response was weakly pro-inflammatory (Lin et al., 2009). It is not 
certain whether postulated pro-inflammatory responses elicited by exogenous CNTF 
in the human retina would be detrimental since CNTF has also been implied to mediate 
beneficial effects in the retina (Fischer, 2008). CNTF’s actions on retinal microglia in 
both healthy and diseased tissue should be investigated in order to gain insight into 
the mechanisms behind CNTF’s neuroprotective actions on retinal neurons.  Research 
should be performed with human retinal tissue if possible. 
Apart from retinal glia, CNTF may elicit retinal protective effects via actions on 
the RPE (Li et al., 2011). The RPE effects were shown only in vitro in primary cultures 
of human fetal RPE cells and proof of in vivo effects is still missing. It is possible that 
CNTF’s effects on the RPE do not need to be direct but may instead be mediated, e.g., 
by retinal glia that in response to exogenous CNTF express and secret other factors 
promoting the survival of RPE. Nonetheless, even though we did not observe 
permeation of labeled rhCNTF across the whole explant (publication II), permeating 
to the RPE in > 24 h to elicit direct effects cannot be ruled out without further studies.  
As most retinal diseases involve activation of Müller glia and reactive gliosis 
(Xue et al., 2011), CNTF may be considered a rather universal treatment approach for 
retinal neurodegeneration, even though its efficacy in earlier clinical trials in GA and 
RP patients was insufficient. Due to the often complex etiologies of retinal diseases, 
their successful treatment may require multiple therapeutics with different modes of 
action. In this context, complex actions of CNTF on retinal glia are of utmost interest. 
Further, as seen with CNTF and GDNF treatment with axotomized RGCs in vivo 
(Flachsbarth et al., 2018), it is realistic to assume that activating multiple trophic 
signaling pathways with the co-administration of CNTF and other growth factors 
could result in synergistic treatment effects.  
In summary, effects of CNTF on retinal glia and neurons are complex and are 
incompletely understood. Neuroprotective effects of CNTF on retinal neurons may 
have both direct and indirect glial cell-mediated components. Permeation of labeled 
rhCNTF into the neural retina shows that the protein distributes to layers with 
recognized CNTF-responsive cells (publication II), implying that the protein’s 
availability to such cells is not a limitation to any direct actions. 
 
Retinal delivery of CNTF. As biologicals fail to permeate to the posterior eye 
segment after topical administration and since the blood-ocular barriers prevent their 
entry from the circulation, direct intravitreal administration is necessary (Shatz et al., 
2018). As there are risks involved with IVT administration and as many posterior 
segment diseases require repeated administration, there is an urgent and unmet need 
to develop methods to prolong the effects and injection intervals for biologicals. 
With CNTF, various approaches for sustained intraocular delivery have been 
explored (Ghasemi et al., 2018). For example, an approach where CNTF expressed as 
a fusion protein with a binding partner was injected together with a hydrogel that was 
covalently modified with a corresponding binding target, resulting in a sustained 
intravitreal release of bioactive CNTF over at least one week (Delplace et al., 2019). 
Furthermore, an engineered fusion protein consisting of hCNTF and sCNTFRα, 




expressing cells, and it was speculated that as it was lacking a synthetic peptide linker 
it would not be recognized as non-self nor be immunogenic (März et al., 2002). ‘as 
this fusion protein can affect non-CNTFRα expressing cells, it would be of great 
interest to study whether it elicits more universal trophic effects on retinal cells than 
CNTF alone. Since Hyper-CNTF has a Mr of over 80 kDa, its intravitreal half-life is 
expected to be longer compared to CNTF, although this may also have an impact on 
the retinal permeation of the protein. 
Renexus® is the approach closest to reaching the clinical practice. Initially 
showing only moderate efficacy in GA and RP patients (Zhang et al., 2011; Kauper et 
al., 2012), a recent phase II trial showed retinal degeneration, photoreceptor loss and 
reading speed loss were significantly reduced in Renexus® treated eyes in patients 
with MacTel 2 (Chew et al., 2019). Such differences in drug efficacy against different 
retinal conditions may be explained by their etiologies. Unlike other conditions, 
MacTel 2 is associated with Müller cell pathologies and thus better coincides with the 
proposed actions of CNTF (Wubben et al., 2018).  
Although Renexus® has proceeded to phase II studies in glaucoma patients with 
phase III studies in MacTel 2 patients pending, the implantation and implant removal 
requires precise surgery. There is still need for less invasive approaches for the 
sustained intraocular delivery of CNTF and other biologicals. Furthermore, in addition 
to the various stresses imparted on biologicals during production processes, they may 
be exposed to various harsh and destabilizing stresses also during the preparation of 
drug delivery systems as well as during intravitreal drug release (Jiskoot et al., 2012). 
Therefore, it is necessary to carry out characterization of the protein and its stability 
as well as extensive scrutinization for the potential for immunogenicity and aggregate 
formation in the context of the developed delivery systems. 
9.4 General considerations for the future 
There is a pressing need for developing new treatments for the neurodegenerative 
diseases of the retina, as most of them still lack efficient treatments. As these diseases 
often exhibit a very slow and (in earlier stages) asymptomatic progress, developed 
treatment strategies should match such disease progression. Furthermore, patient 
stratification is of paramount importance, although the clinical assessment of the 
symptoms and disease status is not always straightforward in the heterogenous and 
complex retinal diseases. Therefore, one of the central challenges is to define the 
optimal timeframe for treatments; on one hand to pinpoint when treatments should be 
initiated to achieve maximal benefits, and on the other hand when disease progression 
is too advanced for clinically meaningful outcomes with therapeutic intervention. 
Hence, the identification and monitoring of clinically relevant endpoints and 
biomarkers is essential to benchmark and monitor disease progression and efficacy of 
therapies.  
There are currently numerous ophthalmologic biologicals in development. As 
their retinal penetration remains poorly understood, elucidation of the involved factors 
could greatly benefit the research in both academia and industry. Herein, we envision 
the ex vivo retinal explants utilized to systematically investigate how different 




biologicals. Increased understanding of the retinal permeation could be utilized in the 
rational design and engineering of new biologicals for ophthalmology.  
Regardless of remarkable advances in the field, the development and production 
of recombinant proteins is often time-consuming and frequently requires process 
optimization to achieve desirable yields of a protein with adequate stability and 
functionality. Furthermore, features like immunogenicity cannot be properly studied 
during preclinical animal studies and, thus, they are often revealed only later during 
clinical trials. Therefore, it is important to develop methods for early detection of 
immunogenicity of lead biologicals. Then, different proteins and engineered variants 
could be tested early on to alter and abolish immunogenicity.  
Protein aggregates are major contributors to immunogenicity of therapeutic 
proteins. Although this phenomenon is widely recognized, it is incompletely defined 
and complex. Aggregation takes place via different simultaneous mechanisms at 
varying rates but is also highly dependent on the protein in question. As various stress 
factors during protein production and storage can induce the formation of the 
aggregates, early identification of aggregation propensity in candidate molecules is of 
interest. To achieve this, it is necessary to define relevant descriptors for protein 
stability and aggregation that can be monitored, for example, with different 
spectroscopic techniques during production. Different approaches could be utilized 
during early development to rapidly screen for the druggability and producibility of 
candidate biologicals in a smaller scale, and later to help avoid aggregate formation 
during larger scale processing. 
All in all, early detection of immunogenic and aggregation propensity in 
therapeutic proteins in the initial phases of development is essential in addressing and 
mitigating their impacts. As both are common culprits for clinical trial failures, an 
altogether better understanding of these phenomena could help in thwarting their 
impact, direct the development process, and curb the costs therein. In conclusion, 
combining various established methodologies with new and innovative approaches is 







This thesis focused on the development of biologicals and on their use in ophthalmic 
conditions, using rhCNTF as a model protein. The following key conclusions were 
reached: 
 
1. Upon codon optimization and factorial screening, various suitable 
conditions for the soluble expression of rhCNTF in E. coli were found. 
2. An optimized approach was chosen for the larger scale expression of 
rhCNTF. High yields of soluble, correctly folded, and biologically active 
rhCNTF were purified. 
3. Upon screening of suitable formulations for the long-term storage of 
rhCNTF, two were chosen for further studies. Stability assessment with 
rhCNTF indicates citrate buffer to be the best candidate for further 
development. 
4. Labeled rhCNTF permeates into the neural retina in both explant models in 
24 h. Direct neuroprotective effects on CNTFRα expressing RGCs and 
photoreceptors are therefore possible. 
5. rhCNTF is expressed in both CFPS systems, with a proof-of-concept for 
intein-mediated capture and light-mediated release of rhCNTF 
demonstrated. 
6. Our protein production platform may be utilized for the streamlined 
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Table S3. Photocleavage of NpuDnaEC16 peptides. 
Peptide  Cleavage time (min) % of main peak AUC remaining tr of main peak (min) 
PEP2 
0 100 10.75 
5 72 10.75 
15 58 10.75 
30 39 10.77 
PEP3 
0 100 10.61 
5 26 10.62 
15 16 10.61 
30 8 10.60 
PEP4 
0 100 11.83 
5 22 11.84 
15 11 11.84 
30 9 11.84 
PEP6 
0 100 11.15 
5 41 11.07 
15 40 11.08 
30 30 11.06 
PEP7 
0 100 11.87 
5 43 11.88 
15 39 11.78 
30 25 11.78 
PEP8 
0 100 10.61 
5 55 10.62 
15 42 10.62 
30 22 10.62 
 

